




Pharmaceutical Assistance
Contract for the Elderly



Managing insomnia in older adults

Evidence-based strategies to improve treatment and
reduce benzodiazepine use



Managing insomnia in older adults

Evidence-based strategies to improve treatment and reduce benzodiazepine use

Principal Consultant: Jacqueline Geer, M.D., and Olivera Bogunovic-Sotelo, M.D.

Series Editors: Benjamin N. Rome, M.D., M.P.H. (co-principal editor), Christopher Worsham, M.D., M.P.H., (co-principal editor), Ellie Grossman, M.D., M.P.H., Jerry Avorn, M.D., Christopher Cai, M.D., Dawn Whitney, M.S.N./Ed., R.N., Ellen Dancel, PharmD, M.P.H.

Medical Writer: Stephen Braun

Alosa Health is a nonprofit organization which accepts no funding from any pharmaceutical company. None of the authors accepts any personal compensation from any pharmaceutical manufacturer.

This work is the result of independent research and collaboration from the authors. No computer algorithms or artificial intelligence was used in the creation of this document.

These are general recommendations only; specific clinical decisions should be made by the treating clinician based on an individual patient's clinical condition.

Alosa Health

Managing insomnia in older adults

Accreditation and Credit Designation:

In support of improving patient care, this activity has been planned and implemented by Harvard Medical School and Alosa Health. Harvard Medical School is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Harvard Medical School designates this enduring material for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Harvard Medical School designates this enduring material for a maximum of 1.00 ANCC contact hour(s), of which 1.00 is eligible for pharmacology credit.

Harvard Medical School designates this knowledge-based activity for a maximum of 1.00 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN#: JA0000216-9999-24-004-H01-P

Activity Overview:

The primary goal of this educational program is to address the challenge of effectively managing insomnia in older adults, with an emphasis on reducing the use of benzodiazepine and benzodiazepine-like medications when possible and appropriate. It reviews fundamental aspects of sleep architecture and the myriad ways normal sleep can be disrupted. The varied physical and mental roots of insomnia are covered, and the full range of pharmacologic and non-pharmacologic treatment options will be reviewed. The latest evidence-based recommendations for the use of benzodiazepine and benzodiazepine-like medications will be presented, along with practical strategies for safely reducing the use of these problematic medications in older adults.

The educational program includes a written evidence report (print monograph) and several non-CME/CE components:

- The written evidence report (print monograph)
- Summary document of top 4-5 key messages
- “Academic detailing” educational sessions in clinicians’ offices with trained outreach educators (pharmacists, nurses, physicians) who present the material interactively
- Reference cards for easy access to key materials
- Patient education information (brochure/tear off sheets)

The program’s goal is to critically review and synthesize the most current clinical information on these topics into accessible, non-commercial, evidence-based educational material, to be taught interactively to providers by specially trained clinical educators.

Target Audience:

The educational program is designed for primary care physicians practicing internal medicine, primary care, family practice, and geriatrics, and other health care professionals who deliver primary care.

Learning Objectives:

After completing this activity, participants will be able to:

- Describe how sleep patterns change with age
- Assess for treatable causes of sleep problems
- Use cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment for patients with chronic insomnia
- Select a medication for insomnia based on the safety profile in older adults
- Review the risks of long-term medications for insomnia, particularly when prescribing benzodiazepines and benzodiazepine receptor agonists (Z-drugs) for older patients
- Discuss tapering and discontinuing benzodiazepines or Z-drugs whenever the risks outweigh the benefits of treatment

Disclosure Policy:

All individuals in a position to control the content of this activity have been asked to disclose any relationship they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships have been mitigated.

This material is provided by Alosa Health, a nonprofit organization which accepts no funding from any pharmaceutical company. No commercial support has been received for this activity. The Independent Drug Information Service (IDIS) is supported by the PACE Program of the Department of Aging of the Commonwealth of Pennsylvania.

Faculty and Planners:

Jacqueline Geer, M.D., Instructor of Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine Dr. Geer has no relevant financial relationships to disclose.

Olivera Bogunovic-Sotelo, MD, Assistant Professor of Psychiatry, Harvard Medical School. Dr. Bogunovic-Sotelo has no relevant financial relationships to disclose.

Benjamin N. Rome, M.D., M.P.H., is an Instructor in Medicine at Harvard Medical School, a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital, and a primary care physician. Dr. Rome has no relevant financial relationships to disclose.

Christopher Worsham, M.D., M.P.H. Assistant Professor of Medicine at Harvard Medical School, a Teaching Associate at the Harvard Medical School Department of Health Care Policy, and a pulmonologist and critical care physician at Massachusetts General Hospital. Dr. Worsham discloses no financial relationships relevant to the content of this document.

Ellie Grossman, M.D., M.P.H., is an Instructor in Medicine at Harvard Medical School, the Medical Director of Primary Care/Behavioral Health Integration and an Attending Physician at the Cambridge Health Alliance. Dr. Grossman has no relevant financial relationships to disclose.

Jerry Avorn, M.D., is a Professor of Medicine at Harvard Medical School and Chief Emeritus of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital. An internist, he has worked as a primary care physician and geriatrician and has been studying drug use and its outcomes for over 40 years. Dr. Avorn has no relevant financial relationships to disclose.

Christopher Cai, M.D. is an internal medicine resident at Brigham and Women's Hospital. Dr. Cai has no relevant financial relationships to disclose.

Dawn Whitney, M.S.N./Ed., R.N. is a Clinical Educator at Alosa Health. She is a lecturer in the School of Nursing and Health Sciences at the University of Massachusetts - Boston and Bouvé College of Health Sciences at Northeastern University. She has no relevant financial relationships to disclose.

Ellen Dancel, Pharm.D., M.P.H., is the Director of Clinical Materials Development at Alosa Health. Dr. Dancel has no relevant financial relationships to disclose.

Stephen R. Braun, B.A., is a medical writer based in Amherst, MA. Mr. Braun has no relevant financial relationships to disclose.

Reviewers

Katherine A. Dudley, M.D., M.P.H., is an Instructor in Medicine at Harvard Medical School and is a pulmonologist and critical care physician at Massachusetts General Hospital. Her clinical focus includes equitable care delivery to improve sleep related health. Dr. Dudley has no relevant financial relationships to disclose.

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have reported no relevant financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Media used:

Printed educational material.

Instructions for Participation and Credit:

There are no fees to participate in this activity. To receive credit, participants must (1) read the statements on target audience, learning objectives, and disclosures, (2) study the educational activity, and (3) complete the post-test and activity evaluation. To receive *AMA PRA Category 1 Credit™*, ANCC contact hours, or Continuing Pharmacy Education (CPE) participants must receive a minimum score of 70% on the post-test.

Tests should be submitted to Alosa Health via email, mail or fax; to complete the evaluation and claim your certificate visit myce.hms.harvard.edu. Credits for pharmacists will be uploaded into CPE Monitor® within 60 days from the date the learner completed the activity.

Email: cme@alosahealth.org

Mailing address:

Alosa Health
20 Park Plaza, Suite 821
Boston, MA 02116

Fax: 857-350-9155

The activity will take approximately 1.00 hour to complete.

Activity publication date: **April 15, 2024**

Termination date: **April 14, 2027**

Please email any questions to **cme@alosahealth.org** or call **(617) 948-5997**.

Table of Contents

Introduction	1
Insomnia definition and epidemiology	1
Impacts of insomnia	3
Sleep architecture in older adults	4
Assessing sleep problems	4
Managing acute insomnia	8
Sleep hygiene	8
Short-course CBT-I	8
Pharmacotherapy	9
Managing chronic insomnia	9
Cognitive behavioral therapy for insomnia	9
Evidence for CBT-I effectiveness	11
Overcoming barriers to the use of CBT-I	12
Medications for insomnia.....	15
Dual orexin receptor antagonists	15
Doxepin and other antidepressants	16
Melatonin receptor agonists	18
Z-drugs	19
Benzodiazepines	20
Cannabis	23
Antihistamines	24
Selecting and managing medications for sleep.....	24
Reducing benzodiazepine and Z-drug use in insomnia.....	26
Helping patients taper and stop benzodiazepines or Z-drugs	28
Benzodiazepine use disorder	31
Putting it all together	33

Appendix I: 30-day costs for insomnia medications	34
References	35

Introduction

Life in 21st-century industrialized societies is filled with an array of stimuli and conditions that can, to one degree or another, disrupt or impair the circadian sleep cycles and sleep patterns that evolved over millions of years in vastly different environmental contexts.¹ In anthropological studies approximately 2% of members of hunter-gatherer tribes in Namibia (N=27) and Bolivia (N=45) reported symptoms of chronic insomnia², compared with rates ranging from 10% to 30% in industrial societies.³ Sleep-disrupting aspects of contemporary life include the use of physiologically stimulating prescription or non-prescription substances (including caffeine⁴), work-related stress,⁵ shift-work employment,⁶ the evening use of short-wavelength-light producing electronic devices,^{7,8} non-natural patterns of temperature and light cycles,³ substance use disorders,⁹ chronic medical conditions,¹⁰ and anxiety and mood disorders.¹¹ Bi-directionality of causation can be involved in some of these factors, but this does not negate the significant role that these and many other forces have on the common appearance in primary care of patients presenting with complaints of insomnia. Indeed, the complexity and diversity of factors related to insomnia make this condition one of the more challenging for primary care clinicians to accurately diagnose and effectively treat, particularly in older adults.¹²

Although non-pharmacological treatments for insomnia, particularly cognitive behavioral therapy for insomnia (CBT-I), are effective and widely recommended as first-line approaches, such treatments remain under-used and pharmacological treatment with benzodiazepine and benzodiazepine-like medications is common.¹³ The percentage of ambulatory visits by people with a benzodiazepine on their medication list grew, in a study of 386,457 U.S. outpatient visits, from 3.8% in 2003 to 7.4% in 2015.¹⁴ A national survey of drug use in 2022 showed that 11.6% of adults ≥65 years used a benzodiazepine in the past year, and 0.5% reported misuse of a benzodiazepine in the past year.¹⁵ Deaths related to benzodiazepine overdose have increased recently as well: a 42.9% rise from 2019 to 2020, which includes a 21.8% increase related to prescribed benzodiazepines (from 921 to 1,122 per 100,000 emergency department [ED] visits) and a 519% increase related to use of benzodiazepines other than as prescribed (from 51 to 316 per 100,000 ED visits).¹⁶

In addition to the risk of overdose, benzodiazepines pose significant risks, particularly in older adults, including cognitive deficits, falls, physiologic dependence, and higher mortality.¹⁷ Prescriptions for benzodiazepine receptor agonists (also known as Z-drugs) have increased in recent years and are also associated with a similar range of adverse effects, including higher mortality.¹⁸⁻²⁰ Ironically, many primary care clinicians express dissatisfaction with available pharmacological options and favor reducing the use of benzodiazepines, Z-drugs, and other sleep medications.²¹

This evidence document discusses the management of insomnia in older adults, with a detailed look at chronic insomnia and ways it can be effectively treated in the primary care setting while minimizing potential harms related to the use of certain classes of medications commonly used to treat insomnia.

Insomnia definition and epidemiology

Insomnia is defined as a persistent difficulty with sleep initiation, duration, or quality despite adequate sleep opportunity that results in a related daytime consequence or concern.²² Patients may present with a wide range of symptoms including: difficulty falling asleep at bedtime, waking at night and having difficulty going back to sleep, or waking too early and being unable to get back to sleep.


Reported sleep problems may overlap or be experienced differently over time. The presence of daytime symptoms that trouble the patient such as tiredness, problems with attention or memory, or disturbed mood are key components of insomnia.

In the past, a distinction was drawn between “primary” insomnia and insomnia secondary to a psychiatric, medical, or other type of sleep disorder. The most recent revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), however, omits this distinction because of the recognized difficulty of determining cause from effect in many cases of insomnia.¹⁰ Insomnia can be a symptom of another disorder, but it may also precipitate or be a risk factor for new-onset psychiatric disorders.²³

Insomnia prevalence varies across studies due to differences in definitions, sample populations, and reporting procedures. Rates from 5% to 50% have been reported, with prevalence generally higher in women than men.¹⁰ For example, in a cross-sectional study in 6,961 household residents aged ≥60 years, the overall prevalence of “disturbed sleep” was 33.7%, with the condition being more prevalent in women (37.2%) than in men (27.4%).²⁴

When more strict diagnostic criteria are used, prevalence rates range from 6% to 10%.¹⁰ Prevalence tends to increase with age. For example, a study of 1,005 adults in Greece found increasing prevalence of insomnia with age, with women having higher levels in every age group except adults aged 25-34.²⁵

Figure 1. Insomnia prevalence with age and gender²⁵



Complaints about sleep are relatively common in older adults. A multi-center study of 9,282 participants ≥65 years old assessed rates of five sleep complaints: trouble falling asleep, waking up, awaking too early, needing to nap, and not feeling rested.²⁶ More than 50% of participants said they experienced at least one sleep complaint. Insomnia in this study was defined as reporting trouble falling asleep and/or waking up too early and not being able to fall asleep again “most of the time.” Using this definition, between 23% and 34% had symptoms of insomnia. Between 7% and 15% percent said they rarely or never felt rested after waking up in the morning.

Although common in older adults, insomnia and other sleep difficulties are not universal and should not be dismissed as normal changes from aging. Many sleep problems arise from aspects of poor health that,

when corrected, can lead to resolution of the sleep issues. This was demonstrated in a 3-year epidemiologic study of 6,899 adults age ≥ 65 years with insomnia.²⁷ In this study using older data, 7% of those reporting insomnia occurred in the absence of associated medical, psychological, or behavioral risk factors. Of the nearly 2,000 participants with chronic insomnia (symptoms ≥ 3 days a week for ≥ 3 months) at baseline, almost half no longer reported symptoms on follow-up, and these participants reported improved health, suggesting that resolution of underlying problems can lead to resolution of insomnia symptoms.

The prevalence of insomnia, as well as racial disparities in self-reported trouble sleeping, may be increasing with time, though more research is needed.^{28,29} The age-adjusted prevalence of insomnia in the U.S. increased from 17.4% in 2007 to 18.8% in 2012, with the largest relative increase among people aged 25-34 years (49% increase).³⁰

Impacts of insomnia

In the short term, insomnia is associated with:¹⁰

- fatigue/tiredness
- hypersensitivity to noise and light
- low energy/motivation
- irritability
- heightened emotional reactivity
- reduced optimism and self-esteem

Across longer time frames, insomnia has been linked to the following mental and physical conditions:³¹

- anxiety disorders
- depressive disorders
- suicidality
- hypertension
- type 2 diabetes
- impaired immune functioning
- migraine and tension-type headache
- cardiac events including myocardial infarction and coronary heart disease

Although this evidence document focuses on older adults, it is worth pointing out that insomnia is also associated with issues typically more relevant in younger adults such as absenteeism,³² lost work productivity,³³ and occupational accidents.³⁴

BOTTOM LINE: Insomnia is a very common concern of patients seen in primary care and can arise from a wide range of sleep-disrupting features of contemporary life. Insomnia prevalence increases with age and is generally more prevalent in women. Insomnia is associated with a host of mental and physical conditions or concerns. Successful treatment of insomnia may resolve troublesome or harmful conditions and, conversely, successful treatment of some physical or emotional problems may help resolve insomnia.

Sleep architecture in older adults

Normal sleep architecture consists of transitions between four kinds of sleep: stage 1 (light, or transitional sleep characterized by alpha waves on electroencephalogram [EEG] recordings); stage 2 (comprising approximately half of sleep time and characterized by spindles and/or K-complexes on EEG); stage 3 (deep sleep characterized by theta waves); and Rapid Eye Movement (REM) sleep (dreaming sleep with EEG patterns similar to waking).³⁵ REM sleep is generally more prominent in the second half of the night or total sleep period.

Aging is associated with changes in the timing, duration, and quality of sleep. In general, older adults fall asleep faster but sleep less and have more frequent awakenings throughout the night, compared to younger adults. Other changes are summarized in Table 1.

Table 1. Changes in sleep with aging³⁵

Measurement	Definition	Normal range	Change with age
Sleep latency	Time from lights out to sleep onset	<20 minutes	Unchanged or reduced
Total sleep time	Total time asleep	7-9 hours	Reduced
Sleep efficiency	Proportion of time in bed asleep	>85%	Reduced
Wake after sleep onset	Time spent awake in bed after initially falling asleep	<15% of time in bed	Increased

The National Sleep Foundation, in a review of available evidence, made the following recommendations for sleep duration, which follow a pattern of decreased need for sleep with advancing age: 14-17 hours for newborns, 12-15 hours for infants, 11-14 hours for toddlers, 9-11 hours for school-aged children, and 8-10 hours for teenagers, and 7-9 hours for adults aged ≥ 18 years.³⁶

Assessing sleep problems

Routine screening for sleep complaints may not be common among primary care clinicians. One study involving 101 patients found that only 20% of the encounters involved screening for insomnia.³⁷ Screening for sleep problems can be as simple as asking “Are you having any problems with sleep?” or the use of some variation on Item 3 of the Patient Health Questionnaire-9, which asks if the patient has had “trouble falling or staying asleep, or sleeping too much.”³⁸ A more complete assessment can be obtained by using the Insomnia Severity Index (ISI).³⁹ The components of an effective sleep history include not only questions about sleep itself, but a full medical history, a social history (e.g., employment, substance use), and a psychiatric assessment.⁴⁰

When a patient reports a problem with sleep, the following domains should be evaluated:³⁸

- nature of the problem (i.e., trouble with sleep-onset, sleep-maintenance, or both)
- frequency of the problem (i.e., nightly vs. sporadic)
- chronicity of the problem (i.e., days, weeks, months, years)
- patient’s sleep schedule and habits (i.e., sleep opportunity and hygiene)

When discussing a patient's typical sleep schedule ask about potentially significant characteristics and factors such as:

- length of time it takes to fall asleep
- number of awakenings each night
- presence of nocturia
- timing and duration of naps
- variability in schedules (e.g., over weekends or due to shift work)
- pre-bedtime routine (e.g., use of electronic screens, exercise, food intake)
- qualities of the bedroom (e.g., temperature, amount of natural light)
- use of caffeine, alcohol, cannabis, nicotine or other substances potentially related to sleep disturbance
- use of non-prescription sleep aids
- attitude toward sleep (e.g., anxiety/frustration about sleeping or anticipated insomnia)
- recent travel across time zones
- presence of sleepwalking or other abnormal behaviors during sleep

The differential diagnosis for insomnia includes the following, which should be explored in patients who either present with sleep difficulties or respond positively to a broad screening question such as the one suggested above:⁴¹

- mental health conditions (e.g., depression, anxiety, post-traumatic stress disorder)
- medical conditions affecting sleep (e.g., heart failure, arthritis, chronic pain, gastro-esophageal reflux, nocturia, pregnancy, menopause)
- timing of certain medications (e.g., diuretics or stimulants too late in the day)
- other sleep disorder (e.g., sleep apnea, circadian rhythm disorder, restless leg syndrome)
- substance use disorder (e.g., alcohol, cocaine, opioids, amphetamines)

Diagnosing insomnia using the most recent American Academy of Sleep Medicine (AASM) criteria requires the presence of each of the following three major criteria, with the duration of symptoms determining whether the insomnia is acute (i.e., <3 months) or chronic (i.e., ≥3 days per week for ≥3 months):²²

- **The patient or caregiver reports difficulty related to initiating or maintain sleep as desired including:**
 - difficulty initiating or maintaining sleep
 - waking up earlier than desired
 - resistance to going to bed on an appropriate schedule
 - difficulty sleeping without caregiver attention
- **The patient or caregiver reports a daytime consequence or concern related to nighttime sleep difficulty such as:**
 - fatigue/malaise
 - attention, concentration, or memory impairment
 - impaired social, family, occupational, or academic performance
 - mood disturbance/irritability
 - daytime sleepiness
 - behavioral problems
 - reduced motivation/energy/initiative

- proneness for errors/accidents
- concerns about or dissatisfaction with sleep
- **The reported sleep/wake complaints cannot be explained by a plausible alternative such as from:**
 - inadequate sleep opportunity (i.e., not enough time allotted for sleep)
 - inadequate circumstances (i.e., sleep environment is not conducive to sleep)
 - another sleep-related disorder (e.g., anything listed in the differential diagnosis above, such as circadian rhythm disorder or sleep apnea)
 - shift work
 - environmental factors
 - homelessness

Affirmative or positive findings on general assessments of presenting sleep difficulties may warrant further explorations, either by a primary care clinician or via referral to a sleep specialist or mental health provider. Assessment tools and techniques that may be used to provide more data on a patient's sleep disorder include sleep diaries, actigraphy and/or wearable technologies to assess movement during sleep; polysomnography (PSG), home sleep testing (HST), and formal questionnaires.

Sleep diaries allow patients to record details of their sleep and sleep-related variables over time (typically a week or two). Paper or electronic diaries are relatively low-cost, simple to use, and were shown in a study with 50 insomnia patients to have high sensitivity and specificity for insomnia symptoms compared to polysomnography (92.3% and 95.6% respectively).⁴² Results from a study of 53 college students in Brazil showed that 7 days of diary use was sufficient for a reliable assessment of sleep time.⁴³ One way to evaluate data from sleep diaries is with sleep efficiency (SE), which is the ratio of total sleep time to the time spent in bed. In healthy adults, SE is typically around 85%.³⁵ A free, printable version of a 2-week sleep diary is available from sleepeducation.org.

Actigraphy uses wearable devices incorporating an accelerometer to measure sleep-wake cycles over multiple days and nights. Although not routinely indicated for diagnosing insomnia, actigraphy can augment sleep diary data, although the devices may also overestimate sleep duration.⁴⁴ Actigraphy may be useful for patients who believe they do not sleep at all (sleep-state misperception) and to differentiate between insomnia (which is characterized by high night-to-night variability in actigraphy-measured motion) and circadian rhythm disorders (which show shifting trends in activity distinct from those seen with insomnia).⁴⁵ Wearable, over-the-counter sleep trackers (e.g., smartwatches, wristbands, rings) are increasingly popular, and data they provide might augment a clinician's other assessment methods, but, to date, high-quality data have not confirmed the validity, accuracy, and reliability of these devices.⁴⁶ In a study comparing a range of wearable devices to polysomnography, the devices were shown to be relatively accurate for determining a simple measure of whether a user was asleep, but the devices were not useful for the assessment of specific sleep stages (compared to polysomnography).⁴⁷

Polysomnography is the gold standard for objective sleep assessment, but it cannot distinguish patients with insomnia from those without it, hence it is not indicated for an assessment of insomnia unless some other sleep-related problem is suspected (e.g., REM sleep behavior disorder, periodic limb movement disorder, or sleep apnea).⁴⁸ Home sleep tests, which measure such variables as airflow, respiratory effort, and oxygen levels, may help in the assessment of sleep-disordered breathing, but, as with polysomnography, such tests are neither necessary nor sufficient to diagnose insomnia.

Questionnaires probing insomnia-related symptoms and/or relevant risk factors and other conditions may have limited use in busy primary care settings, but clinicians should be broadly familiar with the four common tools summarized in Table 2.

Table 2. Questionnaires relevant to the assessment of insomnia

Questionnaire	# of Items	Scoring	Comments
Insomnia Severity Index (ISI) ⁴⁹	7	0–7, no insomnia 8–14, subthreshold insomnia 15–21, moderate insomnia 22–28, severe insomnia	- Used to detect and quantify insomnia severity (patient's perception), assess its impact on daytime functioning, and monitor treatment response - Validated for use as screening tool in primary care - Correlates with sleep diaries, PSG, and patient self-report
Insomnia Symptom Questionnaire ⁵⁰	13	- Only questions 1, 2, or 5 are used to determine the presence, frequency and duration of sleep symptom criteria. - If the answer to all three questions is "yes" insomnia disorder is diagnosed.	Patient-reported outcomes used to diagnose insomnia
Epworth Sleepiness Scale (ESS) ⁵¹	8	- Each item scored on range of 0 (no chance) to 3 (high chance) - Score >10 indicates excessive sleepiness	- Used to measure sleepiness in daily life - Those with insomnia tend not to score above 10 on the ESS
Pittsburgh Sleep Quality Index (PSQI) ⁵²	19, plus optional 5 for bed partner	- Each item scored on range of 0 (not during past month) to 3 (3 or more times/week) - Score >5 considered a significant sleep disturbance	Designed to assess sleep quality and disturbances over 1 month

BOTTOM LINE: Sleep architecture changes with age. Older adults typically fall asleep faster but sleep less and have more frequent awakenings throughout the night compared to younger adults. Assessing sleep problems includes asking not only about sleep itself, but a full medical history, a social history (e.g., employment, substance use), and a psychiatric assessment. Tools and techniques that may provide more data on a patient's sleep disorder include sleep diaries, actigraphy, polysomnography, home sleep testing, and formal questionnaires.

Managing acute insomnia

At the outset of any presentation of insomnia, the first task is to determine if the insomnia is **acute** (i.e., <3 months, usually with an identifiable stressor/precipitant) or **chronic** (i.e., ≥3 days per week for ≥3 months). In general, identify and address any stressors or cooccurring conditions affecting sleep patterns and use non-pharmacological approaches first (i.e., sleep hygiene and/or CBT-I), before prescribing a medication.

For acute insomnia that is severe or associated with significant patient distress, a short course of a sleep-promoting medication may be indicated (see more about the options in Table 13). Close follow-up is recommended to reassess sleep symptoms and to help prevent progression to chronic insomnia.

Sleep hygiene

Sleep hygiene consists of a range of common-sense approaches that can promote normal sleep patterns and which can be included in any overall treatment plan for a primary care patient with either acute or chronic insomnia. Sleep hygiene encompasses a range of behavioral and environmental strategies including:

- keeping a consistent wake time
- going to bed only when feeling sleepy; arising and getting out of bed when one cannot sleep during the desired sleep period
- using the bed solely for sleeping or sex
- avoiding long naps
- keeping the sleep environment cool, quiet, and dark
- limiting alcohol and nicotine use before bed
- avoiding caffeine within 10 hours of bedtime
- avoiding heavy meals or intense exercise before bed
- encouraging patients to not “try too hard” to sleep.³⁸

The impact of caffeine on sleep, although widely recognized, was recently quantified in a study of 100 adults without insomnia or other sleep disorders.⁴ Caffeine consumption (at any time of day) was associated with 397 minutes of nightly sleep compared to 432 minutes of nightly sleep in the same subjects when they did not consume caffeine (mean difference 36 minutes; 95% CI: 25 to 47 minutes).

In its latest set of guidelines for treating insomnia, the AASM recommended that clinicians not use sleep hygiene as a single-component therapy, although it noted that sleep hygiene techniques can be included in multicomponent interventions, including CBT-I or pharmacological treatments.³¹ The AASM based its recommendation on the fact that only two low-quality randomized controlled trials (RCTs) showed clinically meaningful improvements with sleep hygiene alone and each had methodological limitations.^{53,54}

Short-course CBT-I

Although CBT-I typically involves 6-8 sessions spread out over the course of weeks to months, some evidence points to the viability of shorter courses of CBT-I, particularly for acute insomnia. Ellis and colleagues evaluated the effectiveness of a single 60-70 minute session of CBT-I in an RCT of 40 adults who met DSM-5 criteria for insomnia with the exception that the duration of their symptoms was less than 3 months (i.e., acute insomnia).⁵⁵ At one-month follow-up, 60% of the treatment group had remitted (as defined by ISI score <10) compared to 15% of the control group ($P<0.003$). This is broadly consistent with

evidence from a dose-response evaluation of CBT-I in patients with chronic insomnia showing that while a four-session dose of CBT-I was optimal (58.3% patients demonstrated clinically relevant improvements), a single 45- to 60-min session was superior to a two-session dose and a full eight-session dose (43.8% versus 22.2% and 35.3%, respectively).⁵⁶

Pharmacotherapy


Short-term use of sleep-promoting medications may be indicated for patients with acute insomnia, with preferences for agents with relatively lower risks of potentially harmful side effects or risks of dependency (see detailed information below). Although benzodiazepines are not recommended for treating chronic insomnia, they may play a limited role in treating acute insomnia in selected situations (e.g., death of a spouse).

Managing chronic insomnia

As outlined in Figure 2, the broad approach to managing chronic insomnia (i.e., ≥ 3 days per week for ≥ 3 months) is to obtain all relevant histories related to sleep, medications (including non-prescription substances such as caffeine, cannabis, and alcohol), and medical conditions. As with acute insomnia, before treating chronic insomnia with medications or CBT-I, consider if the cause of the insomnia could be addressed with the techniques and strategies of sleep hygiene.

Treatment should be with CBT-I whenever possible, with pharmacotherapy reserved either as second-line treatment or as a short-term adjunct to CBT-I. Patients should be followed closely and regularly, particularly if medications are prescribed, in order to evaluate effectiveness and monitor for undesirable side effects. If the potential harms associated with a medication appear to outweigh the benefits, a careful regimen of deprescribing is warranted, particularly if benzodiazepines or Z-drugs have been prescribed.

Figure 2. Primary care approach to chronic insomnia⁵⁷



Cognitive behavioral therapy for insomnia


CBT-I is a structured, time-limited approach using cognitive and behavioral tools coupled with education to improve sleep efficiency, duration, and quality. It targets the maladaptive thinking processes, beliefs, and behaviors that may underlie insomnia, typically in 6-8 sessions over the course of several weeks to

months.⁵⁸ The essential premise of CBT-I is that it treats the root causes of insomnia, whereas medications of any kind do not and, in fact, may obscure a better understanding of the root causes by masking symptoms and leading to maladaptive sleep associations.

The AASM clinical guidelines³¹ as well as those by the American College of Physicians⁵⁹ recommend CBT-I as first-line treatment for adults with chronic insomnia. This recommendation is based on favorable evidence for the clinical efficacy, durability of benefits, and safety of CBT-I. A number of trials have found that CBT-I is efficacious with durable effects and a favorable benefit-to-risk profile compared to pharmacologic alternatives,⁶⁰⁻⁶² however some trials have not demonstrated efficacy. For example, an RCT compared 6 weeks of treatment with CBT-I, trazodone, or placebo in 923 patients with sleep problems who were undergoing in-center hemodialysis.⁶³ At both 7 and 25 weeks after randomization, no clinically meaningful differences in ISI scores were observed between the three groups.

Components of CBT-I can include **cognitive therapy** to reduce anxiety and to set realistic expectations, **sleep restriction** to decrease time spent in bed and improve sleep efficiency, **stimulus control** (e.g., reserving time in bed for only sleep or sex), **relaxation techniques** (e.g., mindfulness meditation), and **sleep hygiene techniques** (Figure 3).¹⁷

Figure 3. Components of CBT-I⁶⁴



Cognitive therapy is a structured, time-limited approach to identify, expose, and reframe dysfunctional beliefs and attitudes about sleep.⁶⁵ For example, if patients think “I dread going to bed because I won’t be able to sleep,” they may be encouraged to change their thinking to “Even if it takes a little while to fall asleep, I’ll be OK tomorrow.”

Sleep restriction, also known as sleep consolidation, aims to improve sleep efficiency by reducing time spent awake in bed and increasing sleep “drive,” i.e., the felt urge to sleep. Components include using a sleep diary to establish baseline sleep patterns, limiting time in bed to the patient’s average total sleep time plus 30 minutes (as long as the total is >6 hours of sleep), waking at the same time every day regardless of bedtime or if sleepy, and adjusting sleep time in 15 minute increments until sleep is optimized.³¹

Stimulus control promotes a consistent sleep-wake schedule and reduces conditioned responses related to sleep by building associations between the bedroom and sleep. Patients are advised to only use the bed for sleep and sex, to avoid screen time in bed, and to get out of bed at night if they are having trouble sleeping.

Sleep habits refers to using the elements of sleep hygiene to promote sleep, including maintaining a comfortable sleep environment and reducing substances that disrupt sleep.

Relaxation techniques (e.g., mindfulness meditation, yoga nidra) focus attention on the breath and/or on progressive conscious relaxation and awareness of the entire body. These techniques may, or may not, be included in an overall CBT-I strategy. A meta-analysis of 6 randomized trials (total N=330) found that mindfulness meditation, as compared to waitlist or attention control groups, reduced total wake time, sleep onset latency, self-rated sleep scores, and increased sleep quality and sleep efficiency, although none of the differences reached statistical significance.⁶⁶

Yoga nidra is a form of guided meditation to progressively relax the body and allow for slumber if it occurs.⁶⁷ A German study randomized 859 online participants (mean age 38 years, 80% female) to receive an 11-minute yoga nidra guided audio instruction, to be used as needed vs. a waitlist group.⁶⁸ Participants were from a general population and no sleep-related inclusion or exclusion criteria were used. Sleep was assessed with a German version of the PSQI at baseline, 30 days, and 72 days. At both endpoints very small improvements in sleep quality were observed in the yoga nidra group (Cohen's $d = 0.13$ at 30 days and 0.02 at 72 days). On self-reported measures of stress and well-being, yoga nidra participants showed small improvements compared to wait list.

Evidence for CBT-I effectiveness

The evidence base for CBT-I is broad and of sufficiently high quality to support its being recommended as the gold standard treatment for chronic insomnia by professional organizations. A 2015 systematic review and meta-analysis of 20 randomized trials including 1,162 adults with chronic insomnia evaluated CBT-I against inactive comparators and found clinically meaningful benefits for a range of sleep-related outcomes summarized in Table 3.⁶⁹

Table 3. Effects of CBT-I on sleep parameters in patients with chronic insomnia⁶⁹

Sleep parameter	Average CBT-I effect
Sleep onset latency	↓ 19 minutes
Wake after sleep onset	↓ 26 minutes
Total sleep time	↑ 8 minutes
Sleep efficiency	↑ 10%

The effects of CBT-I on quality of life were evaluated in a meta-analysis of 24 studies comprising 1,977 adults with insomnia treated with CBT-I (using varying delivery methods) or a control condition. Robust improvements (reported as effect sizes in quality of life measures) were observed among those treated with CBT-I regardless of delivery mode (Table 4 on the next page).⁷⁰

Table 4. Effects of CBT-I on quality of life in patients with chronic insomnia⁷⁰

CBT-I format	N of studies	Effect size (standardized mean difference)
Face-to-face	11	0.46 (0.01 – 0.90)
Online	8	0.47 (0.01-0.92)
Group	5	0.46 (0.12-0.80)

In evaluations comparing CBT-I to other kinds of treatments, the effect sizes for short-term improvements in insomnia symptoms using CBT-I are comparable to the effect sizes observed in similar analyses of benzodiazepines used to treat insomnia⁷¹, or non-benzodiazepine hypnotics for insomnia⁷², but the benefits of CBT-I are more sustained in the long term and CBT-I has none of the potential adverse effects of medications. Some key papers are summarized here.

A 2024 network meta-analysis of 241 randomized trials including 31,452 adults with chronic insomnia found that, compared to psychoeducation as a referent, CBT-I was associated with the greatest likelihood of insomnia remission (odds ratio [OR] 3.79; 95% CI: 3.21-4.47), followed by behavioral therapy alone (OR 2.50; 95% CI: 1.93-3.24) and cognitive therapy alone (OR 2.49; 95% CI: 1.59-3.92).⁷³

A small RCT of 46 Norwegian adults with chronic insomnia compared six weeks of CBT-I (n = 18) to six weeks of treatment with the benzodiazepine receptor agonist zopiclone (7.5 mg/nightly, n=16) or placebo (n=12).⁷⁴ Sleep diary data were used to determine total wake time, total sleep time, and sleep efficiency, and polysomnography was used to assess slow-wave sleep (deep sleep important for many function such as memory consolidation). CBT-I was associated with improved sleep efficiency (from 81.4% at pretreatment to 90.1% at 6-month follow-up) compared with a decrease from 82.3% to 81.9% in the zopiclone group. Participants in the CBT-I group spent much more time in slow-wave sleep (stage 3) compared with those in other groups, and spent less time awake during the night. Total sleep time was similar in all three groups at six months, although patients receiving CBT-I had better sleep efficiency as assessed with polysomnography than those taking zopiclone. For most outcomes, zopiclone did not differ from placebo.

Overcoming barriers to the use of CBT-I

Despite being widely recommended, CBT-I is not widely prescribed or used. Fewer than 10% of patients with insomnia were referred to CBT-I services in an observational study involving 239 hospital-based clinicians.⁷⁵ The underuse of CBT-I may be related to knowledge barriers (e.g., providers or patients unfamiliar with CBT-I) and logistical barriers (e.g., shortage of trained CBT-I therapists, cost, geographic barriers).^{76,77} The use of CBT-I may also be limited because it involves a high degree of effort and self-discipline, as shown in several qualitative surveys of patients using CBT-I.^{78,79}

A qualitative study conducted in Great Britain among 28 patients with insomnia and 23 treating health professionals found that nearly 60% of the clinicians had either not heard of CBT-I or were unfamiliar with how it worked.⁸⁰ The study also documented some trends in treatment and patient behaviors that apply broadly. For example, clinicians often focused on sleep hygiene, rather than the more comprehensive and effective CBT-I. Clinicians expressed ambivalence about hypnotic drugs but often prescribed them anyway to avoid confrontation with patients or to express empathy with the patient. Patients, on the other hand, reported that they sometimes took hypnotics in ways that were not intended, for example together

with over-the-counter medication. Clinicians sometimes prescribed hypnotics despite concerns about addiction, but at other times withdrew hypnotics abruptly without continuing to treat insomnia symptoms.

Some of the barriers to broader use of CBT-I mentioned above may be ameliorated with the use of technology. Although classic CBT-I is delivered face-to-face by health care providers trained in behavioral sleep medicine, CBT-I delivered digitally (dCBT-I) via smartphones, tablets, or computers is increasingly available and provides a valid option for those who lack access to a sleep psychologist or the funds to pay for in-person CBT-I.⁶⁴ Consumer sleep applications (apps) (i.e., non-prescription programs marketed directly to consumers that claim to perform sleep monitoring, tracking, and sleep-related interventions) have become increasingly prevalent over the past decade,⁸¹ with some suggesting that digital delivery of CBT-I may help address the shortage of trained therapists.⁸² Applications delivering CBT-I in fully-automated and remote ways are available, some of which (e.g., Sleepio, Sleepprate, Sleep Reset) have been shown effective in industry-funded randomized trials.⁸³

A recent network meta-analysis evaluated the efficacy of web-based CBT-I for adults with insomnia compared to usual care.⁸⁴ Fifty-four RCTs comprising 11,815 participants were included. Compared with usual care, web-based CBT-I with a therapist demonstrated significantly longer total sleep time (mean difference [MD]: 23.19 min, 95% CI 18.98-27.39 min), shorter sleep onset latency (MD: -18.76 min, 95% CI -24.20 to -13.31 min), lower rates of waking after sleep onset (MD: -31.40 min, 95% CI -36.26 to -26.55 min), and greater sleep efficiency (MD: 10.37%, 95% CI 8.08%-12.65%).

The results from two other meta-analyses are compared in Table 5, illustrating broad equivalence across sleep outcomes between digitally-delivered CBT-I and traditional CBT-I.^{69,85}

Table 5. Effects on sleep parameters using digital CBT-I vs. traditional CBT-I^{69,85}

Sleep parameter	dCBT-I effect	CBT-I effect
Sleep onset latency	↓ 11 minutes	↓ 19 minutes
Wake after sleep onset	↓ 20 minutes	↓ 26 minutes
Total sleep time	↑ 20 minutes	↑ 8 minutes
Sleep efficiency	↑ 7%	↑ 10%

The results of a network meta-analysis evaluating 86 randomized trials comparing CBT-I, whether digital or in-person, delivered in a variety of formats on a range of daytime symptoms are summarized in Table 6.⁸⁶ Effect sizes for the observed improvements in symptoms ranged from moderate to large.


Table 6. Benefits of digital CBT-I and its components on insomnia-related outcomes⁸⁶

Delivery	Depression	Anxiety/worry	Daytime sleepiness	Fatigue	Daytime and social function	Physical function	Mental state	Quality of life
Individual face-to-face	✓	✓	✓	✓	✓			✓
Group	✓	✓	✓	✓	✓		✓	
Self-help (internet)	✓	✓	✓	✓	✓		✓	
Self-help (internet + therapist)	✓	✓		✓	✓			✓
Self-help (booklet)						---	✓	
Self-help (booklet + therapist)		---	✓	✓	✓	---		---

✓ significant improvement vs. control; --- no studies analyzed for outcome; (blank) no significant improvement vs. control

In a related study, the effects of dCBT-I were shown to persist relatively long after the intervention ended. In a retrospective cohort study of 4,052 patients comparing patients who used a dCBT-I application (Good Sleep) or any kind of medication prescribed for sleep (primarily benzodiazepines, Z-drugs, and trazodone) all sleep outcomes favored dCBT-I at 6-month follow-up (Figure 4).⁸⁷

Figure 4. Sleep-related outcomes at 6-month follow-up in cohort of 4,052 patients⁸⁷



BOTTOM LINE: CBT-I is a structured, time-limited approach to improve sleep efficiency, duration, and quality. Components can include sleep restriction, cognitive therapy, stimulus control, relaxation techniques, and sleep hygiene. The evidence base for CBT-I is robust, and it is recommended as the gold standard treatment for chronic insomnia by professional organizations. Digital options for delivering CBT-I works just as well as traditional in-person CBT-I and may help overcome limited access and availability.

Medications for insomnia

Human sleep/wake cycles are controlled or modulated by many brain regions including the brain stem, limbic system, and prefrontal cortex. Medications used to treat insomnia target these systems, either directly or indirectly. How these medications affect sleep (and their potential adverse effects) depend on which region or sub-region is either activated or inhibited. This section will cover medications with FDA-approved indications for insomnia: dual orexin receptor antagonists (DORAs), benzodiazepines, Z-drugs, doxepin, and ramelteon as well as medications prescribed or used off-label (sedating antidepressants, over-the-counter melatonin, cannabis, and antihistamines).

Regular use of sleep medications is relatively common. In a 2020 National Health Interview Survey of 21,153 adults, 10% of respondents said they take some kind of sleep medication “some days” in the past 30 days, and 6.3% said they take such medication “every day.”⁸⁸

Medications can be used as an adjunct to CBT-I (or components of CBT-I) and some evidence suggests that such combination therapy can be effective. A trial of 160 adults with chronic insomnia randomized patients to either CBT-I alone or CBT-I plus the Z-drug zolpidem (10 mg/night) for 6 weeks and then offered another 6 weeks of CBT-I as extended therapy (with zolpidem use allowed but not mandated).⁸⁹ Sleep outcomes were assessed by sleep diaries and rates of response and remission were evaluated using the ISI. The best outcomes were observed in patients treated with combined therapy initially followed by CBT-I alone compared to patients who continued to take zolpidem during the extended therapy (remission at 6-months 68% vs. 42%, $P=0.04$). Another randomized trial ($N=63$ adults with chronic insomnia), however, found no significant differences in sleep latency or sleep efficiency outcomes comparing CBT-I to a combination of CBT-I and zolpidem.⁹⁰

Dual orexin receptor antagonists

Dual orexin receptor antagonists (DORAs) are the only class of insomnia medications that facilitate sleep by decreasing the wake drive rather than inducing sedation. Orexin is an excitatory brain peptide produced in the hypothalamus that exists in two forms (A and B), which bind to two associated receptors on post-synaptic neurons that project widely and help regulate sleep/arousal cycles in vertebrates.⁹¹ DORAs target orexin signaling by antagonistically binding to both receptors, promoting sleep and sleep maintenance. DORAs have been reported not to adversely affect overall sleep architecture, to shorten REM latency, and to increase total sleep time primarily by increasing duration of REM sleep.⁹²

The three currently-approved DORAs (suvorexant, lemborexant, and daridorexant) are associated with increases in sleep latency and total sleep time and decreases in waking after sleep onset. Table 7 summarizes efficacy data for lemborexant, which is typical of the class, and includes a comparison with zolpidem ER.

Table 7. Efficacy of the DORA lemborexant vs. zolpidem and placebo⁹³

Adults >55	Placebo	zolpidem ER 6.25 mg	lemborexant 5 mg	lemborexant 10 mg
Sleep latency	36 min	37 min*	26 min	23 min
Sleep efficiency	75%	77%	81%	82%
WASO (whole night)	92 min	78 min	69 min	69 min
WASO (second half of the night)	64 min	57 min	49 min	48 min

All results in bold statistically better than placebo; * result statistically worse than placebo

DORAs may have characteristics that favor their use in older adults, compared to benzodiazepines or Z-drugs. An RCT in 1,006 adults aged ≥55 years with insomnia found that lemborexant at the 5 mg dose showed no differences in scores on cognitive performance tests after 1 month vs. placebo and that at both the 5 mg and 10 mg doses lemborexant caused less postural instability than zolpidem.⁹⁴ An analysis of next-morning and across-the-day residual effects of lemborexant across 9 clinical trials showed no significant differences in driving performance vs. placebo, and significantly greater alertness with lemborexant compared to placebo at 6 months follow-up.⁹⁵ DORAs are not currently listed in the American Geriatrics Society's Beers Criteria for potentially inappropriate medications use in older adults.⁹⁶

To date, no evidence has suggested that DORAs are associated with tolerance, withdrawal, or rebound insomnia upon sudden termination.⁹⁷ DORAs are associated, however, with some side effects. In a network meta-analysis of DORAs, the most frequently-reported adverse events were next-day somnolence (rates ranging from 4.1%-13.2%), nasopharyngitis (4%-12%), and headache (4.9%-14.9%).⁹³

Little evidence about the abuse potential of DORAs exists outside of a small study in recreational sedative users. This study randomized 32 such users to three different doses of the DORA lemborexant compared with placebo, zolpidem 30 mg, and suvorexant 40 mg.⁹⁸ Lemborexant demonstrated abuse potential at all studied doses compared to placebo, and scores on the abuse potential of lemborexant were similar to those for zolpidem and suvorexant. In light of the limited evidence, the U.S. Drug Enforcement Agency includes DORAs as Schedule IV controlled substances, similar to Z-drugs.

BOTTOM LINE: DORAs work via a different mechanism of action than benzodiazepines or Z-drugs. They appear as generally effective as Z-drugs but without the same day-after adverse effects. DORAs, unlike benzodiazepines or Z-drugs, are not included on the Beers List of drugs to avoid in older adults. These medications are relatively new, however, and clinical experience with them is still evolving.

Doxepin and other antidepressants

Doxepin is a tricyclic antidepressant that selectively blocks both H1 and H2 histamine receptors at low doses and is FDA-approved for insomnia (Silenor, generics) at doses from 1-6 mg.⁹⁹ While the higher doses indicated for the treatment of depression can cause anticholinergic side effects, low dose doxepin (i.e., <25 mg) used for sleep does not have similar effects and is safe for use in older adults.⁹⁶ The most

frequently-reported side effects include somnolence and headache, although discontinuation rates in clinical trials have been similar to placebo (range 1% to 4%).⁹⁹

In a systematic review of five clinical trials, three of which were conducted in older adults (n=571) doxepin at 3 mg and 6 mg was found to significantly reduce waking after sleep onset and increase total sleep time, but did not affect sleep onset compared to placebo, with no significant differences between doses (Table 8).⁹⁹

Table 8. Sleep outcomes with doxepin in five trials vs. placebo⁹⁹

	All – 3mg	Age >65 – 3mg	All – 6mg	Age >65 – 6mg
Wake after sleep onset	↓ 20 min	↓ 23 min	↓ 28 min	↓ 34 min
Total sleep time	↑ 25 min	↑ 30 min	↑ 30 min	↑ 38 min

Other antidepressants

The use of other antidepressants (e.g., trazodone, amitriptyline) to treat insomnia is widespread, although none are FDA approved for this indication and evidence for their efficacy is limited. In a study of 902 million outpatient visits in 2006, off-label antidepressants were prescribed more frequently (45.1%) than either Z-drugs (43.2%) or benzodiazepines (11.7%).¹⁰⁰ Trazodone was the most-frequently-prescribed off-label antidepressant (17.9%) followed by amitriptyline, mirtazapine, and nortriptyline. Indeed, off-label prescriptions for trazodone for insomnia far exceed the rate of prescription for its approved use as an antidepressant.¹⁰¹ Prescribers may be turning to trazodone and other antidepressants because they are inexpensive, have low potential for misuse, and are not considered controlled substances by the Drug Enforcement Agency.¹⁰¹

Despite its widespread use, trazodone is not recommended by the AASM due to a relative lack of evidence for its efficacy, although some evidence does, in fact, exist. In a Cochrane review of antidepressants for insomnia, three studies (N=370) of trazodone were analyzed and, in meta-analyses, showed a moderate improvement in subjective sleep outcomes vs. placebo (standard mean difference score on visual analog scale or subjective sleep rating -0.34 standard deviations; 95% CI: -0.66 to -0.02).¹⁰² In two studies of trazodone (N=169) using polysomnography to measure sleep efficiency, no significant difference was found compared to placebo (mean difference 1.38 percentage points; 95% CI: -2.87 to 5.63. In two studies, trazodone was more frequently associated with adverse effects of morning grogginess, dry mouth, and thirst. In general, higher doses of tricyclic antidepressants are more likely to exert noradrenergic effects, which could be stimulating, and increase the risks of side effects such as weight gain or dizziness.

BOTTOM LINE: The tricyclic antidepressant doxepin at low doses can be an effective sleep aid with less abuse potential than benzodiazepines or Z-drugs, however they may pose problematic drug interactions, particularly if a patient is on a serotonergic medication. Other antidepressants, such as trazodone, have only weak evidence for efficacy and, thus, are not currently recommended by AASM.

Melatonin receptor agonists

Ramelteon

Ramelteon (Rozerem, generics) is a prescription melatonin receptor agonist that binds to two forms of melatonin receptors in the suprachiasmatic nucleus, which helps control circadian rhythms in sleep and wakefulness.¹⁰³ The affinity of ramelteon for its receptors is 3-16 times higher than that of endogenous melatonin.¹⁰⁴ Ramelteon is reported to have no affinity for dopamine, opiate, serotonin, or GABA receptors, which may limit its range of unwanted side effects and reduce its potential for misuse.¹⁰³ Reported adverse effects with ramelteon include headache, somnolence, fatigue, nausea, and dizziness with the overall incidence of adverse effects in clinical trials being similar to placebo.¹⁰⁵

The efficacy of ramelteon in older adults was evaluated in a clinical trial involving 829 adults aged ≥ 65 years who were randomized to ramelteon at 4 mg or 8 mg doses or placebo taken nightly for 5 weeks.¹⁰⁶ At week 5, sleep latency was 63.4 min with ramelteon 4 mg vs. 70.6 min for placebo ($P=0.028$) and 57.7 min with 8 mg vs. 70.6 min with placebo ($P<0.01$). Total sleep time was increased significantly at 1- and 3-week follow-up, but not at 5-week follow-up. No evidence of rebound insomnia or withdrawal effects were observed after treatment discontinuation.

Another very short-term study of ramelteon randomized 566 patients to an 8 mg dose and 556 to placebo.¹⁰⁷ On nights 1 and 2 sleep latency was 30 minutes in the ramelteon group vs. 43 minutes in the placebo group ($P<0.001$). In this study 3.5% of patients reported somnolence as an adverse effect vs. 0.7% for placebo.

Over-the-counter melatonin

Over-the-counter use of melatonin supplements has risen in recent decades, particularly at doses >5 mg, which is the high end of recommended doses.¹⁰⁸ The latest AASM guidelines do not recommend over-the-counter melatonin based on the very low quality of evidence from three studies evaluating melatonin at 2 mg doses and the lack of any clinically meaningful results from these studies.¹⁰⁹ In addition, a meta-analysis of 24 randomized controlled trials comparing melatonin to a placebo found no significant improvements in sleep onset latency, total sleep time, or sleep efficiency in adults.¹¹⁰

Importantly, melatonin is not FDA-regulated and wide variations in the actual content of the marketed supplements has been reported. In an analysis of 31 melatonin supplements using ultraperformance liquid chromatography for quantification of melatonin and serotonin, melatonin content was found to range from -83% to +478% of the labelled content.¹¹¹ Serotonin (measured because it has historically contaminated OTC melatonin) was identified in eight supplements at levels of 1 to 75 mg (within 10%) in more than 71% of the supplements studied.

BOTTOM LINE: The prescription melatonin agonist ramelteon is modestly effective for improving sleep outcomes and has not been reported to induce rebound insomnia or withdrawal effects on discontinuation. Over-the-counter melatonin is not recommended due to lack of evidence of efficacy and wide variations in the potency and integrity of ingredients among studied brands.

Z-drugs

Z-drugs induce central nervous system depression and have sedative (but not anxiolytic) effects by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA). Z-drugs have been shown in a variety of short-term trials to improve sleep onset, sleep time, and sleep quality (Table 9).

Table 9. Efficacy of Z-drugs on selected sleep outcomes compared to placebo^{109,112,113}

	zolpidem (Ambien)	eszopiclone (Lunesta)	zaleplon (Sonata)
Sleep latency	5-12 min	14 min	10 min
WASO	25 min	10-14 min	No data
Total sleep time	29 min	25-57 min	No data
Sleep quality	Moderate improvement	Moderate-to-large improvement	No improvement

Table 10. Z-drug half-life and potency¹¹⁴

Generic	Brand name	Half-life (hours)	Equivalent potency (lorazepam equivalents)
zaleplon	Sonata	1-2	20
zolpidem	Ambien	2	20
eszopiclone	Lunesta	6	3

Table 11 summarizes currently-available Z-drugs, release formulations, and recommended doses.

Table 11. Z-drug formulations and dosing¹⁰⁹

	Dose	Sleep onset	Sleep maintenance
Zolpidem			
Immediate release (Ambien, generics)	5 mg – women, older adults* 5-10 mg – men	✓	✓
Extended release (Ambien CR, generics)	6.25 mg – women, older adults 6.25-12.5 mg – men	✓	✓
Sublingual (Intermezzo, generics)	1.75 mg – women, older adults 1.75-3.5 mg – men		✓

Eszopiclone (Lunesta, generics)	1-3 mg 2 mg max in older adults	✓	✓
Zaleplon (Sonata, generics)	5-20 mg 5 mg max in older adults	✓	

**The FDA changed its recommended dosing of Z-drugs in women based on evidence that women metabolize these drugs more slowly than men.¹¹⁵*

As with benzodiazepines, Z-drugs are associated with a range of side effects and potential adverse events, the most common of which are dizziness, somnolence, drowsiness, and complex sleep-related behaviors such as sleep-walking, sleep-driving, and sleep-eating. These medications should be avoided in older adults and those with cognitive impairments.⁹⁶ Patients should be cautioned about next-morning impairment for activities that require complete mental alertness (e.g., driving, operating heavy machinery) and warned that these effects may be particularly problematic with eszopiclone and zolpidem CR given their long half-lives. Patients should discontinue use of these medications and avoid others in the same class if they experience an episode of complex-sleep related behavior. No differences in elimination times was observed based on race, ethnicity, or body mass index. Adults over age 65 typically required lower doses due to age-related changes in rates of absorption and elimination.

The risk of fall-related injuries may vary between the available Z-drugs. A case-crossover study among adults aged ≥65 years hospitalized for either fall-related traumatic brain injury (TBI) (N=15,031) or hip fracture (N=37,833) compared injury rates among those prescribed either zolpidem or eszopiclone to matched controls.¹¹⁶ The use of zolpidem, but not eszopiclone, in the month prior to injury was associated with increased risk for TBI (OR 1.87; 95% CI: 1.56-2.25) and hip fracture (OR 1.59; 95% CI: 1.41-1.79).

BOTTOM LINE: As with benzodiazepines, Z-drugs are associated with a range of side effects and potential adverse events, the most common of which are dizziness, somnolence, drowsiness, and complex sleep-related behaviors such as sleep-walking, sleep-driving, and sleep-eating. They are not recommended for use in older adults or anyone with cognitive impairment.

Benzodiazepines

Benzodiazepines are sedative hypnotics that enhance the inhibitory effects of GABA causing central nervous system depression and sedative/anxiolytic effects. Benzodiazepine use is relatively common in older adults, with 10.4% reporting any use in the prior year in a 2021 national survey.¹⁵ Not all benzodiazepines are approved for an indication of insomnia. Those that are include triazolam, temazepam, estazolam, flurazepam, and quazepam.

Benzodiazepines have been shown to slightly reduce sleep latency and nocturnal awakenings, but they also reduce REM sleep.¹¹⁷ Benzodiazepines are associated with a range of adverse effects that may be particularly significant in older adults, including increasing the risk of memory impairment, falls, fractures, motor vehicle accidents, and avoidable emergency department visits.¹¹⁸

Although benzodiazepines are unlikely to cause dementia, they are associated with cognitive impairment. A prospective study followed 10,263 adults aged ≥65 years for 10 years and found an increased risk for cognitive impairment (HR 1.32; 95% CI: 1.04-1.68) but not Alzheimer disease (HR 0.84; 95% CI: 0.63-1.12) or all-cause dementia (HR 0.86; 95% CI: 0.68-1.09).¹¹⁹ Prolonged use of benzodiazepines can lead to physical and psychological dependence, with attendant increased risks of addiction, abuse, and

overdose.¹²⁰ Abrupt discontinuation following prolonged use typically results in withdrawal symptoms of insomnia and anxiety and can lead to life-threatening complications such as seizure.

Benzodiazepines are associated with increased risk of suicide in some patients. An observational study comparing a group of 86 adults aged ≥ 50 years who completed suicide to a control group matched on age, gender, race, and county of residence found that 25% of those who committed suicide used benzodiazepines, compared to 6% of controls (OR 3.1; 95% CI: 1.2-9.9).¹²¹ Another study of 17,608 adults aged ≥ 50 years found a similar increased risk of suicide with benzodiazepine use (adjusted OR 2.0; 95% CI: 1.01-3.94).¹²² Screening older patients for suicide risk is recommended¹²² using a screening tool such as a 4-question tool developed by the National Institute for Mental Health.¹²³


The co-prescription of benzodiazepines and opioids is particularly hazardous. Of the 118,208 overdose deaths involving benzodiazepines that occurred between 2000 and 2019, 83.5% also involved opioids, as assessed by analysis of ICD-10 codes for presence of opioids and other substances.¹²⁴

Benzodiazepines vary considerably in their potencies and half-lives (Table 12). The risk of adverse events can be associated with the half-life of the specific benzodiazepine prescribed. In a cohort study of 5,579 drivers using benzodiazepines matched with 13,256 controls, the risk of traffic accidents increased after initiation of long half-life benzodiazepine and throughout the first year of prescribing, while risk increased only slightly at first with short-half-life benzodiazepines, which then became non-significant after 6 weeks of prescribing (Figure 5).

Table 12. Benzodiazepine half-life and potency¹¹⁴


Generic	Brand name	Half-life (hours)	Equivalent potency (lorazepam equivalents)
oxazepam	Serax	4-15	20
alprazolam	Xanax	6-12	0.5
temazepam	Restoril	8-22	20
lorazepam	Ativan	10-20	1
clonazepam	Klonopin	18-50	0.5
diazepam	Valium	20-100	10
chlorazepate	Tranxene	36-200	15

Figure 5. Risk of traffic accidents in older adults prescribed long- vs. short-half-life benzodiazepines



In addition to these risks, benzodiazepines are only modestly effective for insomnia. A meta-analysis of 45 randomized trials comparing benzodiazepines to either placebo or to another medication (15 of which included patients aged ≥ 65 years) over short time frames (median trial duration 7.5 days) and with small sample sizes (i.e., study Ns ranged from 12-50) found no significant difference in sleep latency (mean decrease 4.2 minutes; 95% CI: -0.7 to 9.2 minutes) and a significantly increased total sleep duration (61.8 minutes; 95% CI: 37.4-86.2 minutes) (Figure 6).¹²⁶

Figure 6. Minimal benefits on insomnia symptoms in meta-analyses of benzodiazepine trials¹²⁶



Analysis of side effects in the meta-analysis found reduced number of nocturnal arousals with benzodiazepines, confirmed with EEG recordings or self-reported rating scales, although these effects waned after 28 days. Adverse effect associated with benzodiazepines included daytime drowsiness,

dizziness, lightheadedness, and cognitive impairments. Drop-out rates were similar between placebo and benzodiazepine groups.

BOTTOM LINE: Benzodiazepines are associated with a range of potential harms including dependence, misuse, driving impairment, cognitive impairment, and increased suicide risk. Short-term use of benzodiazepines (i.e., <1 month) provides only modest clinical efficacy and such use should be intermittent or as-needed, not continuous. Long-term use of benzodiazepines increases the risk for adverse events. Alternative treatments for insomnia should be recommended for patients with insomnia.

Cannabis

The effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) on sleep have not been clearly established due, in part, to the fact that both compounds are found, in varying proportions, in many forms of cannabis (e.g., “flower,” oils, edibles). In a study with 8 healthy adults using purified THC and/or CBD delivered as oral mucosal sprays and using electroencephalographic recordings during sleep, no effects on sleep were observed with 15 mg of THC administered at 10 p.m.¹²⁷ When both THC and CBD were administered (up to 15 mg THC and 15 mg CBD), stage 3 sleep (deep sleep important for many functions) was decreased and wakefulness was increased. In assessments the day after administration of 15 mg THC, memory was impaired, sleep latency was reduced, and subjects reported mood changes and increased sleepiness. In general, 15 mg THC appeared to be sedative, while 15 mg CBD appeared to be alerting.

A recent scoping review of cannabis used for sleep disorders demonstrated the need for much more rigorous evaluations of cannabis efficacy for treating insomnia. Of the 40 studies included in the review, only 25% were RCTs, and only 20% used comparable sleep outcomes.¹²⁸ The use of cannabis was reported to improve sleep in 21% of the studies, to worsen sleep in 48% of studies, showed mixed results related to sleep in 14% of studies and had no impact one way or the other in 17% of studies. A 2022 systematic review of 31 studies reached similar general conclusions. The review found sleep improvements in 7 out of 19 randomized studies and in 7 out of 12 uncontrolled trials, with no significant differences observed between the effects of THC and CBD.¹²⁹ Improved sleep was observed more frequently in studies of patients with pain-related disorders, compared to patients with neurologic, psychiatric, or primary sleep disorders, and no effects on sleep were observed among healthy participants. Heterogeneity in cannabis types, doses, timing of administration, and sleep outcome measures precluded meta-analyses of the data from the studies and such heterogeneities pose challenges to a better understanding of the role that cannabis or its components could play for the treatment of sleep disorders generally.

As with OTC melatonin products, labeling of OTC CBD products has been shown to be often inaccurate, and some degree of contamination with other, unlabeled cannabinoids, have been demonstrated. In an analysis of 84 OTC products containing CBD, 26% contained less CBD than was indicated on the label and 43% had more CBD than was labeled.¹³⁰ In this study, THC was detected in 21% of the products (but was not included on the label).

BOTTOM LINE: The utility of THC and/or CBD for treating chronic insomnia has not been proven and evidence to date is mixed. The common presence of side effects such as memory impairment,

mood changes, and the possibility of worsening insomnia with THC or CBD mean these agents are not recommended as treatments in older adults.

Antihistamines


First generation antihistamines (diphenhydramine, doxylamine) marketed as Benadryl, Unisom, Nytol, Tylenol PM, and many others, are widely-available over-the-counter antihistamines with sedative properties that are commonly used as sleep aids. Because it has strong anticholinergic effects and is a potential deliriant in high doses diphenhydramine is on the Beers list of drugs to avoid in older adults.⁹⁶ In its latest recommendations, AASM recommended against using diphenhydramine for treating insomnia because the overall quality of evidence from meta-analyses was low and because the studies evaluated were industry-sponsored.¹⁰⁹ Adverse effects, including rebound insomnia, were minimal and not significantly different from placebo in the two trials of diphenhydramine considered by the AASM guideline committee.^{131,132}

BOTTOM LINE: First generation antihistamines (diphenhydramine, doxylamine) are not recommended for the treatment of chronic insomnia in older adults due to lack of evidence for efficacy and the possibility of anticholinergic side effects.

Selecting and managing medications for sleep

Not all patients need medications for insomnia, particularly if they can use CBT-I instead. If a medication is needed, the choice of medication should be tailored to each patient. Start by assessing the primary sleep complaint and using that to drive medication choices.

Figure 7: Select the medication option for each patient¹⁰⁹



The Table 13 (on the next page) summarizes information in the sections above to help clinicians select medications most appropriate for older adults.

Table 13. Medications used to treat insomnia

	Treatment (Brand)*	Half life	Quality of evidence	Safe in older adults	Factors for selection
Dual orexin receptor antagonists (DORAs)	daridorexant (Quviviq)	short	Strong	●	- work by decreasing wake drive rather than inducing sedation - somnolence common - better tolerated than Z-drugs¹³³ - expensive
	lemborexant (Dayvigo)	intermediate	Strong	●	
	suvorexant (Belsomra)	intermediate	Strong	●	
Melatonin receptor agonists	ramelteon (Rozerem)	short	Moderate	●	- no residual daytime impairment¹⁰³ - don't take with or after high-fat meal
	melatonin (OTC)	short	Weak	●	- limited efficacy data - concerns about dose and purity
Sedating antidepressants	low-dose doxepin (Silenor)	intermediate	Strong	●	- most effective for sleep maintenance - low dose (1-6 mg) avoids anticholinergic side effects and QTc prolongation¹³⁴
	trazodone (Desyrel)	intermediate	Weak	●	- unclear efficacy data - few side effects at low doses (<50 mg); higher dose increases anticholinergic risk
Z-drugs	zolpidem (Intermezzo, Ambien, Ambien CR)	short intermediate long	Strong	○	- not recommended in older adults, particularly those with cognitive impairment¹³⁵ as they can cause daytime sedation or confusion - do not combine with other sedating medications (e.g., opioids, benzodiazepines)
	eszopiclone (Lunesta)	short	Strong	○	
	zaleplon (Sonata)	short	Strong	○	
Benzodiazepines	alprazolam (Xanax)	intermediate	Weak	✗	- not recommended in older adults¹³⁵ - use only for short periods (<1 month); longer-term use is not effective. - risk of physiologic dependence, tolerance, cognitive impairment, driving problems
	temazepam (Restoril)	intermediate	Moderate	✗	
	clonazepam (Klonopin)	long	Weak	✗	
Antihistamines	diphenhydramine (Benadryl)	long	Weak	✗	- not recommended in older adults due to anticholinergic side effects (e.g., dry mouth, constipation) - included in multiple OTC products (e.g., Tylenol PM, ZzzQuil)


* Generics available for all classes except the DORAs as of April 2024. ✗ – avoid long-term use; ○ – use with caution and monitor for treatment limiting side effects; ● – not known to be unsafe in older adults, although all sleep medications can cause daytime drowsiness.

Reducing benzodiazepine and Z-drug use in insomnia

Benzodiazepines and Z-drugs are only recommended for short-term use (i.e., ≤ 4 weeks) which means clinicians should be prepared to help patients safely discontinue the medications, even if adverse effects are not present.

For patients who have been using benzodiazepines or Z-drugs for longer periods, the decision to taper or discontinue these medications should be tailored based on individual patient risks. A discussion with the patient about discontinuing a benzodiazepine or Z-drug should be undertaken if any of the red flags summarized in Figure 8 are present, or if there is evidence that the patient is using the benzodiazepine or Z-drug with non-prescribed central nervous system depressants (e.g., alcohol, opioids).

Figure 8. Red flags warranting discussion of benzodiazepine or Z-drug discontinuation



Stopping a benzodiazepine, or switching to another class of sleep medication, may be challenging for patients, particularly if they have used a benzodiazepine for a long time.¹³⁶ Psychological dependence is common for sleep medications of any type, but this dependence coupled with physical dependence can create patient resistance to change. Patients must be ready and motivated to change, hence clinicians must share relevant information (e.g., about the potential harms of benzodiazepines) and use non-judgmental, open-ended approaches such as motivational interviewing when discussing the possibility of reducing or stopping a benzodiazepine (Table 14).

Table 14. Increasing motivation to taper benzodiazepines¹³⁷


Action	Provider response
Express concern	• <i>“I would like to take a minute to discuss my concerns about (benzodiazepine name).”</i>
Provide education on potential risks	• <i>“Because of your [age or other risk factors], I am concerned that the use of (benzodiazepine name) may put you at increased risk for [relevant repercussion].”</i>
Assess patient’s readiness to begin taper process	• <i>“What do you see as the possible benefits of stopping or reducing the dose? What concerns do you have about stopping? What can we do together to help address these concerns?”</i> • If patient indicates no desire to change, provide information about potential risks. <i>“What would be a reason you might consider changing from (benzodiazepine name) to (name of recommended alternative)?”</i>
Negotiate the plan	• <i>“What changes are you willing to make to reach this goal?”</i> • <i>“Would you be willing to talk to one of my colleagues to learn about other options to support your changes?”</i>

Withdrawal symptoms (e.g., anxiety, dysphoria, dizziness, excitability) and rebound insomnia should be expected with discontinuation of a benzodiazepine, with such symptoms typically more likely when stopping short-acting benzodiazepines. Symptoms typically start 1-2 days after discontinuation of short-acting benzodiazepines and may last for days to weeks (Figure 9). Withdrawal and rebound insomnia typically start 2-7 days after stopping long-acting benzodiazepines.

Symptoms specific to benzodiazepine withdrawal:

- perceptual disturbances
- depersonalization, derealization
- hallucinations
- distortion of body image
- tingling, numbness
- sensory hypersensitivity (light touch)
- muscle twitches, jerks, fasciculation
- tinnitus

Figure 9. Course of benzodiazepine withdrawal¹³⁸



Scales to assess withdrawal symptoms include:

- Benzodiazepine Withdrawal Symptom Questionnaire
- Clinical Institute Assessment of Withdrawal Benzodiazepines
- Physician Withdrawal Checklist
- Ashton Withdrawal Symptoms Rating Scale
- Composite Benzodiazepine Discontinuation Symptom Scale

Helping patients taper and stop benzodiazepines or Z-drugs

Primary care clinicians can help older patients taper and stop benzodiazepines regardless of whether they meet the formal criteria for benzodiazepine use disorder. In general, use the benzodiazepine the patient is already prescribed, support the taper with another strategy to treat insomnia (e.g., CBT-I or a less-risky medication such as a DORA, doxepin, or ramelteon), and select an appropriate taper strategy (see Table 15 below).

When planning a benzodiazepine taper consider how fast the taper should be, whether to taper the existing benzodiazepine or switch to a longer-acting benzodiazepine, and whether to use any adjuvant medications or interventions during the taper.

Z-drugs can usually be stopped more rapidly than benzodiazepines.¹³⁹ Patients taking a high dose or who have chronic use of Z-drugs can be tapered at a rate of 25% decrease every 7 days. Therapeutic doses of Z-drugs do not require a taper, although when these drugs are stopped patients should be advised to expect worse sleep on the first night, with improvements quickly thereafter.¹³⁹

Historically, some clinicians recommended switching patients from a short-acting to a longer-acting benzodiazepine during a taper to help minimize side effects, but evidence suggests that this is not necessary. A 1991 study randomized 68 patients taking a daily dose of 2-16 mg of diazepam or

equivalent dose to either lorazepam (short-acting), bromazepam (short-acting), or diazepam (long-acting).¹⁴⁰ Patients were maintained on a stable dose for 4 weeks, then tapered by 25% every 2 weeks to discontinuation at 10 weeks. Few differences in withdrawal symptoms were observed between groups, although symptoms were worse if the patient had been taking the benzodiazepine for >5 years.

Taper schedules vary, and none have been compared in RCTs. The possible approaches are summarized in Table 15, with details following below:

Table 15. Benzodiazepine taper strategies

	Benefits	Challenges
Abrupt taper	None	not recommended; may result in withdrawal symptoms
Fast taper ¹⁴¹ (reduce dose by 25% of original dose each week)	• Shorter taper schedule (i.e., 1 month) • Reasonable success (46% stopped benzodiazepines)	Some people may have withdrawal symptoms
Symptom guided taper ¹⁴² (Variable taper duration based on patient factors)	• Minimizes withdrawal symptoms • Most successful taper (70% stopped benzodiazepines)	• Requires more frequent assessment of symptoms • Variable taper duration based on patient factors (may be weeks to months)
Partial dose taper (EMPOWER) ¹⁴³ (tablet dose reduction on a set calendar schedule)	Clear protocol for patients and clinicians to follow	• Lengthy taper (may be months or more) • Less successful than symptom guided or fast taper (38% stopped or reduced dose)

Abrupt withdrawal of a benzodiazepine is not recommended once tolerance has developed because it exposes the patient to the consequences of a surge in excitatory nervous system activity and all of the withdrawal symptoms previously described, including rebound insomnia but also more potentially severe reactions such as convulsions or acute psychotic states.¹¹⁴

The **fast taper** approach was evaluated in the previously-described 2003 study that randomized patients who were unsuccessful in attempting to quit benzodiazepine use on their own to one of three groups: a tapering schedule of 25% reduction/week, that same tapering schedule with the addition of group CBT, or usual care.¹⁴¹ At 3-month follow-up, 62% of the group using the 25%/week taper had successfully quit compared to 58% in the CBT group and 21% in the usual care group.

A 1987 study evaluated a **symptom-guided approach** to withdrawal in 50 patients seeking to quit their benzodiazepine use.¹⁴² Patients were switched to an equivalent dose of diazepam and tapered on individually-tailored schedules (duration range 7 days to 15 months). Various drugs were used temporarily for symptom control (e.g., tricyclic antidepressants, clonidine, analgesics) and patients had frequent contact with clinicians who provided repeated encouragement. Outcomes were assessed at 10 months to 3.5 years after initiation of taper. One patient failed to achieve complete withdrawal, and three relapsed to benzodiazepine use. Of the total group, 48% were deemed to have an “excellent” outcome

(i.e., “fully recovered”) and 22% were deemed to be “much better” (i.e., they still had some symptoms but these did not interfere with their lives).

The **Eliminating Medications Through Patient Ownership (EMPOWER) trial** randomized 303 patients (mean age 75 years) currently using benzodiazepines (60% for insomnia) to an intervention consisting of an 8-page educational booklet presenting rationales for benzodiazepine discontinuation, a tapering schedule, and suggestions to talk to a prescriber or pharmacist, or to a wait list group.¹⁴³ After 6 months those in the intervention group had significantly higher rates of benzodiazepine discontinuation or dose reductions. The number-needed-to-treat for one patient to reduce or discontinue their benzodiazepine dose was 3.7.

Similar results were seen in a trial of patients aged ≥ 60 years with insomnia who were taking benzodiazepines or Z-drugs for at least three months.¹⁴⁴ Patients were randomized to receive either minimal intervention (i.e., an explanation of the dangers of long-term treatment with their prescribed drug), a “tapering down intervention” (TDI) group who received a table with a recommended tapering schedule, or a control group of matched patients who received no intervention. After 3 months the sedative medications were discontinued in 15.2% of the minimum intervention group, 27.3% of the TDI group, and 1.8% of the control group.


Taper with substitution

Adding a program of CBT-I to a tapering protocol appears to be more effective than a gradual taper alone, as evidenced by a meta-analysis of 8 trials (N=582) showing that combining CBT-I with gradual tapering of benzodiazepines over three months was more effective for stopping the drugs than gradual tapering alone (relative risk [RR] 1.68; 95% CI: 1.19-2.39), although the differences in effect sizes became insignificant after 12 months.¹⁴⁵ The group receiving the combined approach showed greater short-term improvement in their insomnia symptoms than the group getting gradual tapering alone (g - 0.69; 95% CI: -1.09 to -0.28). A more recent study, however, came to a different conclusion. Voshaar and colleagues randomized 180 adults trying to discontinue long-term benzodiazepine use to a tapering protocol plus CBT-I, the tapering protocol alone, or usual care.¹⁴¹ At three months, 58% of the group tapering with CBT-I had successfully discontinued, 62% of the group tapering without CBT-I were successful, and 21% of the usual care group were successful. Tapering, regardless of adjunctive CBT-I, was clearly superior to usual care ($P=0.002$).

Although a gradual benzodiazepine taper can reduce the severity of withdrawal symptoms, some patients experience distress or discomfort during withdrawal and the use of non-benzodiazepine adjunctive medications may address some of these concerns.

For example, transitioning to a Z-drug as a strategy for weaning off of a benzodiazepine may help reduce insomnia-related withdrawal symptoms during a taper. A trial of 1,022 adults (mean age 44 years) using benzodiazepines for insomnia were randomized to either a gradual substitution to zopiclone over 35 days; abrupt substitution of zopiclone for the benzodiazepine; or continuation with the benzodiazepine on a tapering schedule.¹⁴⁶ After 50 days patients in both zopiclone groups had less severe sleep-related symptoms than the group in the benzodiazepine group, and, after the withdrawal stage was completed, 18% in the gradual Z-drug switch group and 19% of the abrupt Z-drug switch group resumed benzodiazepine use, compared to 29% resumption in the benzodiazepine taper group ($P<0.01$) (Figure 10).

Figure 10. Z-drug substitution reduces sleep-related withdrawal symptoms during taper¹⁴⁶



Benzodiazepine use disorder

The DSM-5 provides guidance to help primary care clinicians determine if a patient's pattern of use and their symptoms constitute a use disorder (Table 16). For patients meeting the DSM-5 criteria, referral to addiction treatment may be warranted (if available).

Table 16. DSM-5 criteria for benzodiazepine use disorder¹⁴⁷

A problematic pattern of sedative, hypnotic, or anxiolytic use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period:	
• Sedatives, hypnotics, or anxiolytics are often taken in larger amounts or over a longer period than was intended.	
• A persistent desire or unsuccessful efforts to cut down or control sedative, hypnotic, or anxiolytic use.	
• A great deal of time is spent in activities necessary to obtain the sedative, hypnotic, or anxiolytic; use the sedative, hypnotic, or anxiolytic; or recover from its effects.	
• Craving, or a strong desire or urge to use the sedative, hypnotic, or anxiolytic.	
• Recurrent sedative, hypnotic, or anxiolytic use resulting in a failure to fulfill major role or obligations at work, school, or home.	
• Continued sedative, hypnotic, or anxiolytic use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of sedatives, hypnotics, or anxiolytics.	
• Important social, occupational, or recreational activities are given up or reduced because of sedative, hypnotic, or anxiolytic use.	
• Recurrent sedative, hypnotic, or anxiolytic use in situations in which it is physically hazardous.	
• Continued sedative, hypnotic, or anxiolytic use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the sedative, hypnotic, or anxiolytic.	
• Tolerance: need for markedly larger doses to achieve effect, diminished effect at constant dose	Not included for patients taking a benzodiazepine, or other sedative, hypnotic or anxiolytic, as prescribed
• Withdrawal: characteristic withdrawal syndrome, use benzodiazepines to relieve withdrawal	

BOTTOM LINE: Benzodiazepine or Z-drug discontinuation is feasible with even minimal kinds of interventions. Tapering approaches that use symptom-guided approaches or the use of CBT-I as an adjuvant may increase the likelihood of success. Prognostic factors for success include short duration of use and an absence of psychiatric symptoms. Use of short-term, non-addictive medications for relief of withdrawal symptoms (e.g., anxiety, insomnia) may be helpful.


Putting it all together

Insomnia is a common complaint of older adults in primary care, and it can be challenging to assess and treat due to the complexity and diversity of factors that can interfere with sleep, ranging from environmental conditions to mental and physical illnesses. Non-pharmacological strategies to treat insomnia, specifically CBT-I, are recommended as first-line therapies by professional organizations because they are effective, durable, and have none of the side effects of many sleep medications, particularly benzodiazepines and Z-drugs. A range of digital CBT-I approaches are now available that can help overcome barriers such as lack of trained CBT-I providers or lack of geographic access.

If CBT-I is either not effective or is unavailable, dual orexin receptor antagonists, doxepin, or ramelteon are pharmacologic agents with proven efficacy and more favorable side effect profiles in older adults compared to benzodiazepines and Z-drugs, which should be avoided due to increased risks for confusion, falls, fractures, impairments in activities of daily living, and cognitive dysfunction.

Discuss tapering and discontinuing benzodiazepines or Z-drugs whenever the risks of their use appear to outweigh the benefits of treatment. Use motivational interviewing techniques to clarify the patient's level of motivation to change and their expectations for the process of transitioning to either no medication or an alternative medication.

Appendix I: 30-day costs for insomnia medications



CR = controlled release; SL = sublingual

Prices from goodrx.com, January 2024. Listed doses are based on Defined Daily Doses by the World Health Organization, when available, or package inserts; they should not be used for dosing in all patients. All doses shown are generics when available, unless otherwise noted. These prices are a guide; patient costs will be subject to copays, rebates, and other incentives.

References

1. O J, Pugh-Jones C, Clark B, Trott J, Chang L. The Evolutionarily Mismatched Impact of Urbanization on Insomnia Symptoms: a Short Review of the Recent Literature. *Curr Psychiatry Rep.* 2021;23(5):28.
2. Yetish G, Kaplan H, Gurven M, et al. Natural sleep and its seasonal variations in three pre-industrial societies. *Curr Biol.* 2015;25(21):2862-2868.
3. Siegel JM. Sleep function: an evolutionary perspective. *Lancet Neurol.* 2022;21(10):937-946.
4. Marcus GM, Rosenthal DG, Nah G, et al. Acute Effects of Coffee Consumption on Health among Ambulatory Adults. *N Engl J Med.* 2023;388(12):1092-1100.
5. Garefelt J, Platts LG, Hyde M, Magnusson Hanson LL, Westerlund H, Akerstedt T. Reciprocal relations between work stress and insomnia symptoms: A prospective study. *J Sleep Res.* 2020;29(2):e12949.
6. Brito RS, Dias C, Afonso Filho A, Salles C. Prevalence of insomnia in shift workers: a systematic review. *Sleep Sci.* 2021;14(1):47-54.
7. Chang AM, Aeschbach D, Duffy JF, Czeisler CA. Evening use of light-emitting eReaders negatively affects sleep, circadian timing, and next-morning alertness. *Proc Natl Acad Sci U S A.* 2015;112(4):1232-1237.
8. Lockley SW, Brainard GC, Czeisler CA. High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light. *J Clin Endocrinol Metab.* 2003;88(9):4502-4505.
9. Provencher T, Lemyre A, Vallieres A, Bastien CH. Insomnia in personality disorders and substance use disorders. *Curr Opin Psychol.* 2020;34:72-76.
10. Morin CM, Jarrin DC. Epidemiology of Insomnia: Prevalence, Course, Risk Factors, and Public Health Burden. *Sleep Med Clin.* 2022;17(2):173-191.
11. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. *J Psychiatr Res.* 2003;37(1):9-15.
12. Postuma RB. Beyond One-Size-Fits-All: Testing Insomnia Treatments in Special Populations. *Ann Intern Med.* 2024.
13. Morin CM. Cognitive behavioural therapy for insomnia (CBTi): From randomized controlled trials to practice guidelines to implementation in clinical practice. *J Sleep Res.* 2020;29(2):e13017.
14. Agarwal SD, Landon BE. Patterns in Outpatient Benzodiazepine Prescribing in the United States. *JAMA Netw Open.* 2019;2(1):e187399.
15. Substance Abuse and Mental Health Services Administration. *Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health.* Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2022.
16. Liu S, O'Donnell J, Gladden RM, McGlone L, Chowdhury F. Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines - 38 States and the District of Columbia, 2019-2020. *MMWR Morb Mortal Wkly Rep.* 2021;70(34):1136-1141.
17. Soong C, Burry L, Greco M, Tannenbaum C. Advise non-pharmacological therapy as first line treatment for chronic insomnia. *BMJ.* 2021;372:n680.
18. Parsaik AK, Mascarenhas SS, Khosh-Chashm D, et al. Mortality associated with anxiolytic and hypnotic drugs-A systematic review and meta-analysis. *Aust N Z J Psychiatry.* 2016;50(6):520-533.
19. Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. *BMJ.* 2014;348:g1996.
20. Milani SA, Raji MA, Chen L, Kuo YF. Trends in the Use of Benzodiazepines, Z-Hypnotics, and Serotonergic Drugs Among US Women and Men Before and During the COVID-19 Pandemic. *JAMA Netw Open.* 2021;4(10):e2131012.
21. Siriwardena AN, Apekey T, Tilling M, Dyas JV, Middleton H, Orner R. General practitioners' preferences for managing insomnia and opportunities for reducing hypnotic prescribing. *J Eval Clin Pract.* 2010;16(4):731-737.
22. American Academy of Sleep Medicine. *International Classification of Sleep Disorders 3rd Edition, Revised.* Darien, IL 2023.
23. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. *J Affect Disord.* 2011;135(1-3):10-19.
24. Blay SL, Andreoli SB, Gastal FL. Prevalence of self-reported sleep disturbance among older adults and the association of disturbed sleep with service demand and medical conditions. *Int Psychogeriatr.* 2008;20(3):582-595.

25. Paparrigopoulos T, Tzavara C, Theleritis C, Psarros C, Soldatos C, Tountas Y. Insomnia and its correlates in a representative sample of the Greek population. *BMC Public Health*. 2010;10:531.
26. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: an epidemiologic study of three communities. *Sleep*. 1995;18(6):425-432.
27. Foley DJ, Monjan A, Simonsick EM, Wallace RB, Blazer DG. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. *Sleep*. 1999;22 Suppl 2:S366-372.
28. Hisler GC, Muranovic D, Krizan Z. Changes in sleep difficulties among the U.S. population from 2013 to 2017: results from the National Health Interview Survey. *Sleep Health*. 2019;5(6):615-620.
29. Wang S, Rossheim ME, Nandy RR. Trends in prevalence of short sleep duration and trouble sleeping among US adults, 2005-2018. *Sleep*. 2023;46(1).
30. Ford ES, Cunningham TJ, Giles WH, Croft JB. Trends in insomnia and excessive daytime sleepiness among U.S. adults from 2002 to 2012. *Sleep Med*. 2015;16(3):372-378.
31. Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med*. 2021;17(2):255-262.
32. Daley M, Morin CM, LeBlanc M, Gregoire JP, Savard J, Baillargeon L. Insomnia and its relationship to health-care utilization, work absenteeism, productivity and accidents. *Sleep Med*. 2009;10(4):427-438.
33. Kessler RC, Berglund PA, Coulouvrat C, et al. Insomnia and the performance of US workers: results from the America insomnia survey. *Sleep*. 2011;34(9):1161-1171.
34. Shahly V, Berglund PA, Coulouvrat C, et al. The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. *Arch Gen Psychiatry*. 2012;69(10):1054-1063.
35. Feinsilver SH. Normal and Abnormal Sleep in the Elderly. *Clin Geriatr Med*. 2021;37(3):377-386.
36. Hirshkowitz M, Whiton K, Albert SM, et al. National Sleep Foundation's updated sleep duration recommendations: final report. *Sleep Health*. 2015;1(4):233-243.
37. Senthilvel E, Auckley D, Dasarathy J. Evaluation of sleep disorders in the primary care setting: history taking compared to questionnaires. *J Clin Sleep Med*. 2011;7(1):41-48.
38. Yamamoto M, Lim CT, Huang H, Spottswood M, Huang H. Insomnia in primary care: Considerations for screening, assessment, and management. *J Med Access*. 2023;7:27550834231156727.
39. Gagnon C, Belanger L, Ivers H, Morin CM. Validation of the Insomnia Severity Index in primary care. *J Am Board Fam Med*. 2013;26(6):701-710.
40. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. *J Clin Sleep Med*. 2008;4(5):487-504.
41. Riemann D, Espie CA, Altena E, et al. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. *J Sleep Res*. 2023;32(6):e14035.
42. Rogers AE, Caruso CC, Aldrich MS. Reliability of sleep diaries for assessment of sleep/wake patterns. *Nurs Res*. 1993;42(6):368-372.
43. Borba DA, Reis RS, Lima P, et al. How many days are needed for a reliable assessment by the Sleep Diary? *Sleep Sci*. 2020;13(1):49-53.
44. Natale V, Plazzi G, Martoni M. Actigraphy in the assessment of insomnia: a quantitative approach. *Sleep*. 2009;32(6):767-771.
45. Smith MT, McCrae CS, Cheung J, et al. Use of Actigraphy for the Evaluation of Sleep Disorders and Circadian Rhythm Sleep-Wake Disorders: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. *J Clin Sleep Med*. 2018;14(7):1209-1230.
46. de Zambotti M, Cellini N, Goldstone A, Colrain IM, Baker FC. Wearable Sleep Technology in Clinical and Research Settings. *Med Sci Sports Exerc*. 2019;51(7):1538-1557.
47. Miller DJ, Sargent C, Roach GD. A Validation of Six Wearable Devices for Estimating Sleep, Heart Rate and Heart Rate Variability in Healthy Adults. *Sensors (Basel)*. 2022;22(16).
48. Winkelman JW. CLINICAL PRACTICE. Insomnia Disorder. *N Engl J Med*. 2015;373(15):1437-1444.
49. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep Med*. 2001;2(4):297-307.
50. Okun ML, Kravitz HM, Sowers MF, Moul DE, Buysse DJ, Hall M. Psychometric evaluation of the Insomnia Symptom Questionnaire: a self-report measure to identify chronic insomnia. *J Clin Sleep Med*. 2009;5(1):41-51.
51. Scharf MT. Reliability and Efficacy of the Epworth Sleepiness Scale: Is There Still a Place for It? *Nat Sci Sleep*. 2022;14:2151-2156.

52. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res.* 1989;28(2):193-213.
53. Edinger JD, Wohlgemuth WK, Krystal AD, Rice JR. Behavioral insomnia therapy for fibromyalgia patients: a randomized clinical trial. *Arch Intern Med.* 2005;165(21):2527-2535.
54. Sidani S, Epstein DR, Fox M, Collins L. Comparing the Effects of Single- and Multiple-Component Therapies for Insomnia on Sleep Outcomes. *Worldviews Evid Based Nurs.* 2019;16(3):195-203.
55. Ellis JG, Cushing T, Germain A. Treating Acute Insomnia: A Randomized Controlled Trial of a "Single-Shot" of Cognitive Behavioral Therapy for Insomnia. *Sleep.* 2015;38(6):971-978.
56. Edinger JD, Wohlgemuth WK, Radtke RA, Coffman CJ, Carney CE. Dose-response effects of cognitive-behavioral insomnia therapy: a randomized clinical trial. *Sleep.* 2007;30(2):203-212.
57. Rosenberg RP, Benca R, Doghramji P, Roth T. A 2023 Update on Managing Insomnia in Primary Care: Insights From an Expert Consensus Group. *Prim Care Companion CNS Disord.* 2023;25(1).
58. Pigeon WR. Treatment of adult insomnia with cognitive-behavioral therapy. *J Clin Psychol.* 2010;66(11):1148-1160.
59. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med.* 2016;165(2):125-133.
60. Araújo T, Jarrin DC, Leanza Y, Vallières A, Morin CM. Qualitative studies of insomnia: Current state of knowledge in the field. *Sleep Med Rev.* 2017;31:58-69.
61. Cheung JM, Atternäs K, Melchior M, Marshall NS, Fois RA, Saini B. Primary health care practitioner perspectives on the management of insomnia: a pilot study. *Aust J Prim Health.* 2014;20(1):103-112.
62. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med.* 2017;13(2):307-349.
63. Mehrotra R, Cukor D, McCurry SM, et al. Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis : A Randomized Clinical Trial. *Ann Intern Med.* 2024.
64. Erten Uyumaz B, Feijs L, Hu J. A Review of Digital Cognitive Behavioral Therapy for Insomnia (CBT-I Apps): Are They Designed for Engagement? *Int J Environ Res Public Health.* 2021;18(6).
65. Ng L, Cunningham D. Management of insomnia in primary care. *Aust Prescr.* 2021;44(4):124-128.
66. Gong H, Ni CX, Liu YZ, et al. Mindfulness meditation for insomnia: A meta-analysis of randomized controlled trials. *Journal of psychosomatic research.* 2016;89:1-6.
67. Harvard University Center for Wellness and Health Promotion. Yoga Nidra guided meditation audio file. <https://wellness.huhs.harvard.edu/file/1053137>. Accessed March 8, 2023.
68. Moszeik EN, von Oertzen T, Renner KH. Effectiveness of a short Yoga Nidra meditation on stress, sleep, and well-being in a large and diverse sample. *Curr Psychol.* 2022;41:5272-5286.
69. Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunningham D. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. *Ann Intern Med.* 2015;163(3):191-204.
70. Alimoradi Z, Jafari E, Brostrom A, et al. Effects of cognitive behavioral therapy for insomnia (CBT-I) on quality of life: A systematic review and meta-analysis. *Sleep Med Rev.* 2022;64:101646.
71. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. *JAMA.* 1997;278(24):2170-2177.
72. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. *BMJ.* 2012;345:e8343.
73. Furukawa Y, Sakata M, Yamamoto R, et al. Components and Delivery Formats of Cognitive Behavioral Therapy for Chronic Insomnia in Adults: A Systematic Review and Component Network Meta-Analysis. *JAMA Psychiatry.* 2024.
74. Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. *JAMA.* 2006;295(24):2851-2858.
75. Conroy DA, Ebben MR. Referral Practices for Cognitive Behavioral Therapy for Insomnia: A Survey Study. *Behav Neurol.* 2015;2015:819402.
76. Thomas A, Grandner M, Nowakowski S, Nesom G, Corbitt C, Perlis ML. Where are the Behavioral Sleep Medicine Providers and Where are They Needed? A Geographic Assessment. *Behav Sleep Med.* 2016;14(6):687-698.
77. Koffel E, Bramoweth AD, Ulmer CS. Increasing access to and utilization of cognitive behavioral therapy for insomnia (CBT-I): a narrative review. *J Gen Intern Med.* 2018;33(6):955-962.

78. Kyle SD, Morgan K, Spiegelhalter K, Espie CA. No pain, no gain: an exploratory within-subjects mixed-methods evaluation of the patient experience of sleep restriction therapy (SRT) for insomnia. *Sleep Med.* 2011;12(8):735-747.
79. Barnes GL, Lawrence V, Khondoker M, Stewart R, Brown JSL. Participant Experiences of Attending a Community CBT Workshop for Insomnia: A Qualitative Six-Year Follow-Up. *Behav Sleep Med.* 2019;17(2):156-173.
80. Davy Z, Middlemass J, Siriwardena AN. Patients' and clinicians' experiences and perceptions of the primary care management of insomnia: qualitative study. *Health Expect.* 2015;18(5):1371-1383.
81. Ibanez V, Silva J, Navarro E, Cauli O. Sleep assessment devices: types, market analysis, and a critical view on accuracy and validation. *Expert Rev Med Devices.* 2019;16(12):1041-1052.
82. Espie CA, Henry AL. Disseminating cognitive behavioural therapy (CBT) for insomnia at scale: capitalising on the potential of digital CBT to deliver clinical guideline care. *J Sleep Res.* 2023;32(6):e14025.
83. Luik AI, Marsden A, Emsley R, et al. Long-term benefits of digital cognitive behavioural therapy for insomnia: Follow-up report from a randomized clinical trial. *J Sleep Res.* 2020;29(4):e13018.
84. Hasan F, Tu YK, Yang CM, et al. Comparative efficacy of digital cognitive behavioral therapy for insomnia: A systematic review and network meta-analysis. *Sleep Med Rev.* 2022;61:101567.
85. Seyffert M, Lagisetty P, Landgraf J, et al. Internet-Delivered Cognitive Behavioral Therapy to Treat Insomnia: A Systematic Review and Meta-Analysis. *PLoS One.* 2016;11(2):e0149139.
86. Benz F, Knoop T, Ballesio A, et al. The efficacy of cognitive and behavior therapies for insomnia on daytime symptoms: A systematic review and network meta-analysis. *Clin Psychol Rev.* 2020;80:101873.
87. Lu M, Zhang Y, Zhang J, et al. Comparative Effectiveness of Digital Cognitive Behavioral Therapy vs Medication Therapy Among Patients With Insomnia. *JAMA Netw Open.* 2023;6(4):e237597.
88. National Center for Health Statistics. Sleep medication use in adults ages 18 and over: United States, 2020. <https://www.cdc.gov/nchs/products/databriefs/db462.htm#print>. Accessed February 12, 2024.
89. Morin CM, Vallieres A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. *JAMA.* 2009;301(19):2005-2015.
90. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. *Arch Intern Med.* 2004;164(17):1888-1896.
91. Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. *Front Endocrinol (Lausanne).* 2013;4:18.
92. Clark JW, Brian ML, Drummond SPA, Hoyer D, Jacobson LH. Effects of orexin receptor antagonism on human sleep architecture: A systematic review. *Sleep Med Rev.* 2020;53:101332.
93. Rocha RB, Bomtempo FF, Nager GB, Cenci GI, Telles JPM. Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis. *Arq Neuropsiquiatr.* 2023;81(5):475-483.
94. Rosenberg R, Murphy P, Zammit G, et al. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. *JAMA Netw Open.* 2019;2(12):e1918254.
95. Moline M, Zammit G, Yardley J, et al. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials. *Postgrad Med.* 2021;133(1):71-81.
96. By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. *J Am Geriatr Soc.* 2023;71(7):2052-2081.
97. Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. *Neuropsychiatr Dis Treat.* 2021;17:2549-2566.
98. Landry I, Hall N, Aluri J, et al. Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users. *J Clin Psychopharmacol.* 2022;42(4):365-373.
99. Rojas-Fernandez CH, Chen Y. Use of ultra-low-dose (≤ 6 mg) doxepin for treatment of insomnia in older people. *Can Pharm J (Ott).* 2014;147(5):281-289.
100. Lai LL, Tan MH, Lai YC. Prevalence and factors associated with off-label antidepressant prescriptions for insomnia. *Drug Healthc Patient Saf.* 2011;3:27-36.

101. Pelayo R, Bertisch SM, Morin CM, Winkelman JW, Zee PC, Krystal AD. Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal. *J Clin Med*. 2023;12(8).
102. Everitt H, Baldwin DS, Stuart B, et al. Antidepressants for insomnia in adults. *Cochrane Database Syst Rev*. 2018;5(5):CD010753.
103. Zammit GK. Ramelteon: a novel hypnotic indicated for the treatment of insomnia. *Psychiatry (Edgmont)*. 2007;4(9):36-42.
104. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. *Neuropharmacology*. 2005;48(2):301-310.
105. Reynoldson JN, Elliott E, Sr., Nelson LA. Ramelteon: a novel approach in the treatment of insomnia. *Ann Pharmacother*. 2008;42(9):1262-1271.
106. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. *Sleep Med*. 2006;7(4):312-318.
107. Wang-Weigand S, McCue M, Ogrinc F, Mini L. Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis. *Curr Med Res Opin*. 2009;25(5):1209-1213.
108. Li J, Somers VK, Xu H, Lopez-Jimenez F, Covassin N. Trends in Use of Melatonin Supplements Among US Adults, 1999-2018. *JAMA*. 2022;327(5):483-485.
109. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med*. 2017;13(2):307-349.
110. Choi K, Lee YJ, Park S, Je NK, Suh HS. Efficacy of melatonin for chronic insomnia: Systematic reviews and meta-analyses. *Sleep Med Rev*. 2022;66:101692.
111. Erland LA, Saxena PK. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. *J Clin Sleep Med*. 2017;13(2):275-281.
112. Samara MT, Huhn M, Chiochia V, et al. Efficacy, acceptability, and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta-analysis. *Acta Psychiatr Scand*. 2020;142(1):6-17.
113. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. *Journal of general internal medicine*. 2007;22(9):1335-1350.
114. Ashton H. The diagnosis and management of benzodiazepine dependence. *Curr Opin Psychiatry*. 2005;18(3):249-255.
115. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. *J Pharmacol Exp Ther*. 2000;293(2):435-443.
116. Tom SE, Wickwire EM, Park Y, Albrecht JS. Nonbenzodiazepine Sedative Hypnotics and Risk of Fall-Related Injury. *Sleep*. 2016;39(5):1009-1014.
117. Pagel JF, Parnes BL. Medications for the Treatment of Sleep Disorders: An Overview. *Prim Care Companion J Clin Psychiatry*. 2001;3(3):118-125.
118. Tannenbaum C. Inappropriate benzodiazepine use in elderly patients and its reduction. *J Psychiatry Neurosci*. 2015;40(3):E27-28.
119. Nafti M, Sirois C, Kroger E, Carmichael PH, Laurin D. Is Benzodiazepine Use Associated With the Risk of Dementia and Cognitive Impairment-Not Dementia in Older Persons? The Canadian Study of Health and Aging. *Ann Pharmacother*. 2020;54(3):219-225.
120. Kamel NS, Gammack JK. Insomnia in the elderly: cause, approach, and treatment. *Am J Med*. 2006;119(6):463-469.
121. Conwell Y, Duberstein PR, Hirsch JK, Conner KR, Eberly S, Caine ED. Health status and suicide in the second half of life. *Int J Geriatr Psychiatry*. 2010;25(4):371-379.
122. Schepis TS, Simoni-Wastila L, McCabe SE. Prescription opioid and benzodiazepine misuse is associated with suicidal ideation in older adults. *Int J Geriatr Psychiatry*. 2019;34(1):122-129.
123. National Institute for Mental Health. Ask Suicide-Screening Questions (ASQ) Toolkit. <https://www.nimh.nih.gov/research/research-conducted-at-nimh/asq-toolkit-materials>. Accessed February 12, 2024.
124. Kleinman RA, Weiss RD. Benzodiazepine-Involved Overdose Deaths in the USA: 2000-2019. *J Gen Intern Med*. 2022;37(8):2103-2109.
125. Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. *JAMA*. 1997;278(1):27-31.

126. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. *CMAJ*. 2000;162(2):225-233.
127. Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. *J Clin Psychopharmacol*. 2004;24(3):305-313.
128. Amaral C, Carvalho C, Scaranelo A, Chapman K, Chatkin J, Ferreira I. Cannabis and sleep disorders: not ready for prime time? A qualitative scoping review. *J Clin Sleep Med*. 2023;19(5):975-990.
129. Velzeboer R, Malas A, Boerkoel P, et al. Cannabis dosing and administration for sleep: a systematic review. *Sleep*. 2022;45(11).
130. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. *JAMA*. 2017;318(17):1708-1709.
131. Glass JR, Sproule BA, Herrmann N, Busto UE. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. *J Clin Psychopharmacol*. 2008;28(2):182-188.
132. Morin CM, Koetter U, Bastien C, Ware JC, Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. *Sleep*. 2005;28(11):1465-1471.
133. Zhou M, Tang J, Li S, Li Y, Zhao M. Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: A comprehensive dose-response meta-analysis. *Front Hum Neurosci*. 2022;16:1029554.
134. Rojas-Fernandez CH, Chen Y. Use of ultra-low-dose (≤ 6 mg) doxepin for treatment of insomnia in older people. *Can Pharm J (Ott)*. 2014;147(5):281-289.
135. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. *J Am Geriatr Soc*. 2023;71(7):2052-2081.
136. Capiou A, Huys L, van Poelgeest E, et al. Therapeutic dilemmas with benzodiazepines and Z-drugs: insomnia and anxiety disorders versus increased fall risk: a clinical review. *Eur Geriatr Med*. 2023;14(4):697-708.
137. Department of Veterans Affairs. The possible risks of benzodiazepines. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/<https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/508/10-1526-Benzos-Provider-PossibleRisksOfBenzos-P97046.pdf>. Accessed February 12, 2024.
138. NSW Health (Australia). *Drug and Alcohol Withdrawal Clinical Practice Guidelines-NSW*. North Sydney, Australia 2008.
139. Watson NF, Benca RM, Krystal AD, McCall WV, Neubauer DN. Alliance for Sleep Clinical Practice Guideline on Switching or Deprescribing Hypnotic Medications for Insomnia. *J Clin Med*. 2023;12(7).
140. Murphy SM, Tyrer P. A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. *Br J Psychiatry*. 1991;158:511-516.
141. Voshaar RC, Gorgels WJ, Mol AJ, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. *Br J Psychiatry*. 2003;182:498-504.
142. Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. *Br J Addict*. 1987;82(6):665-671.
143. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. *JAMA Intern Med*. 2014;174(6):890-898.
144. Kosto A, Lev D, Reiss N, Meged-Book T, Press Y. Discontinuation of benzodiazepines and Z-drugs in hospitalised population at the age of 60 and above. An open-label randomized controlled trial. *Int J Geriatr Psychiatry*. 2023;38(10):e6012.
145. Takaesu Y, Utsumi T, Okajima I, et al. Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: A systematic review and meta-analysis. *Sleep Med Rev*. 2019;48:101214.
146. Lemoine P, Ohayon MM. Is hypnotic withdrawal facilitated by the transitory use of a substitute drug? *Prog Neuropsychopharmacol Biol Psychiatry*. 1997;21(1):111-124.
147. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*. Arlington, VA 2013.

About this publication

These are general recommendations only; specific clinical decisions should be made by the treating clinician based on an individual patient's clinical condition.



This material is provided by **Alosa Health**, a nonprofit organization which accepts no funding from any pharmaceutical company.

This material was produced by Jacqueline Geer, M.D., M.H.S., Instructor of Medicine (Pulmonary, Critical Care and Sleep Medicine) at Yale School of Medicine; Olivera Bogunovic-Sotelo, M.D., Assistant Professor of Psychiatry; Benjamin N. Rome, M.D., M.P.H., Instructor in Medicine (co-principal editor); Christopher M. Worsham, M.D., Assistant Professor of Medicine (co-principal editor); Jerry Avorn, M.D., Professor of Medicine; Ellie Grossman, M.D., M.P.H., Instructor in Medicine; Christopher Cai, M.D., Clinical Fellow in Medicine; all at Harvard Medical School; Dawn Whitney, R.N., M.S.N., Lecturer at Northeastern University and University of Massachusetts, Boston; and Ellen Dancel, Pharm.D., M.P.H., Director of Clinical Materials Development at Alosa Health. Drs. Avorn, Cai, and Rome are physicians at the Brigham and Women's Hospital and Dr. Worsham practices at Massachusetts General Hospital, both in Boston. Dr. Geer practices at Yale New Haven Hospital and Dr. Bogunovic-Sotelo is a psychiatrist at McLean Hospital in Belmont, MA. Dr. Grossman practices at the Cambridge Health Alliance. None of the authors accept any personal compensation from any drug company.

Medical writer: Stephen Braun



Pharmaceutical Assistance
Contract for the Elderly